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ABSTRACT
The present research work is based on the formulation, optimization and
characterization of nanoparticulate drug delivery system. The main rationale of the
work is to formulate a targeted drug delivery system with enhanced drug entrapment
efficiency. Here the drug of interest is Irinotecan hydrochloride trihydrate, an
antineoplastic agent while the polymer used is poly lactide -o - glcolic acid (PLGA),
a biodegradable polymer. The analytical method development is carried out using
acetonitrile and phosphate buffer saline. The formulation optimization is also carried
out optimizing its various process and formulation parameters. Different organic
solvents were tried and various surfactants were used to optimize the nanoparticulate
formulation. The size range and zeta potential was measured using Malvern zeta
sizer. The lyofilization was carried out using two different cryoprotectants .
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CHAPTER 1
INTRODUCTION
1.1     TARGETED DELIVERY OF ANTICANCER AGENTS
Much effort has been expended to improve the selectivity of cancer
chemotherapeutic agents, and significant improvement in patient survival has been
achieved in recent years. Nevertheless, the developments of novel selective agents
and new ways of delivering both old and new agents are possibly the most important
goals of modern anticancer research82.
Targeted cancer chemotherapy aims to direct adequate concentration of the
chosen agent to tumor cells while affecting as few healthy cells as possible. In
principle, this can be achieved by passive or active targeting. Passive targeting
exploits the enhanced permeability and retention (EPR) characteristics of tumor
vessels.  Rapidly  growing  tumors  develop  extensive  vasculatures  to  meet  their
requirement for nutrient supply and waste disposal, but the blood vessels are
abnormally hyper-permeable, with defective architecture and impaired lymphatic
drainage. Circulating macromolecular drugs or particulate delivery systems that
have difficulty permeating normal blood vessels can extravasate through such tumor
blood vessels, and they become entrapped due to the impaired lymphatic drainage in
tumor tissues61.
               Consequently, the EPR effect can be applied to facilitate the selective
accumulation of an appropriately designed drug delivery system at a tumor site. To
achieve efficient accumulation, the delivery system must also avoid systemic
clearance by the reticuloendothelial system (RES), usually achieved by controlling
the size and surface properties of the delivery systems. To avoid RES uptake, a
hydrophilic surface and small particle size under 100 nm are the most often
mentioned requirements). Active targeting, on the other hand, is often achieved by
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exploiting the differences in membrane biochemistry between cancer and normal
cells. Active targeting of a drug to cancer cells may involve the conjugation of
tissue- or cell-selective ligands that bind specifically with receptors on the surface of
tumor cells, examples of which include lectin-carbohydrate and antibody-antigen
interactions. Selectivity is ensured by choosing ligands that bind to antigens or
receptors that are either uniquely expressed or over-expressed on the target cells
compared to normal tissues. To increase the payload to be delivered to the tumor
site, the drug may be concentrated in a carrier, e.g. nanoparticles, which is then
conjugated with the targeting ligand61.
The concept of drug targeting, suggested by Paul Ehrlich almost a century
ago, considered a hypothetical ‘magic bullet’ as an entity consisting of two
components — the first one should recognize and bind the target, while the second
one should provide a therapeutic action in this target. Currently, the concept of
magic bullet includes a coordinated behavior of three components: (a) drug; (b)
targeting moiety; and (c) pharmaceutical carrier used to multiply the number of drug
molecules per single targeting moiety. Pharmaceutical carriers include soluble
polymers, microcapsules, microparticles, cells, cell ghosts, lipoproteins, liposomes,
and micelles. All of them can be made targeted in one-way or another30,82 .
               The recognition of the target can occur on the level of a whole organ, on
the level of certain cells specific for a given organ, or even on the level of individual
components characteristic of these cells, such as cell surface antigens. The most
universal form of target recognition is the recognition on the molecular level, based
on the fact that every organ or tissue certain compounds (antigens) can be found that
are  specific  only  for  the  organ  of  interest.  For  successful  targeting,  another
compound can be used as a transporting unit, which is capable of the specific
interaction with the specific target component (for example, a monoclonal antibody
against the target antigen). Basing on this principle, numerous systems for drug
targeting have been constructed capable of the delivery of pharmaceuticals to the
variety of tissues and organs30.
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1.2 NANOPARTICULATE SYSTEMS FOR DRUG DELIVERY
Nanoparticles are engineered submicron-sized systems that range in size
from a few nanometers to several hundred nanometers depending on their intended
use. A variety of organic and inorganic materials, including polymers, lipids,
ceramic and metals, have been used to construct nanoparticles. Most inorganic
nanoparticles have a central core (usually metallic) and a protective organic surface
coating. Organic nanoparticles include liposomes and other lipid-based carriers,
polymeric nanoparticles, micelles and various ligand-targeted products. Structurally,
nanoparticles have also been classified as dendrimers, micelles, nanospheres,
nanocapsules, liposomes, fullerenes and nanotubes. Based on their manufacturing
methods and materials used, the size and shape of nanoparticles vary.
Therapeutic drugs may be incorporated into nanoparticles by surface
attachment or encapsulation. Nanoparticulate drug delivery systems are highly
versatile. Drug payloads range from small molecular weight drugs to
macromolecules, from highly water-soluble agents to strongly hydrophobic drugs.
The method of delivery may vary from the simple, localized delivery using a
catheter-based approach to sophisticated targeted delivery whereby the conjugation
of biospecific ligand onto the nanoparticle surface could direct drug delivery to the
tissue of interest. In addition, the small particle size of nanoparticles yields a high
surface area per unit weight ratio that can greatly facilitate drug dissolution and
absorption in the gastrointestinal fluids. Nanoparticulate systems have been
demonstrated to improve drug bioavailability, facilitate drug solubilization, sustain
drug effect in target tissues and improve the stability of therapeutic agents. Since the
latter half of the 1980s, nanoparticles have been studied as carriers for drug delivery
to challenge many diseases, including cancer, HIV, and diabetes. Much of the
research has concentrated on improving the bioavailability of drugs with poor
absorption characteristics and providing controlled release of drugs46. Therapeutic
agents of interest are incorporated into polymer nanoparticles either by physical
entrapment within the polymeric matrix or by surface adsorption or conjugation. The
size and surface properties of the nanoparticles determine their fate in the human
body. Unless there is intended drug delivery to the RES, the size and surface of the
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nanoparticles must be designed to avoid RES clearance. Nanoparticles smaller than
100 nm in diameter have been found advantageous in this respect. So is the coating
of nanoparticles with the hydrophilic polymer, polyethylene glycol (PEG) Targeted
drug delivery is realized by surface conjugation with a biospecific ligand, which
may also favorably modify the intracellular disposition of the nanoparticles.
Biocompatible, hydrophilic or hydrophobic polymer nanoparticles with surface-
pendant amine, carboxyl or aldehyde groups have been fabricated for further bio-
conjugation. A wide variety of ligands, such as folic acid, antibody, and aptamers
have been used for surface modification of polymeric nanoparticles to impart cancer
cell targeting capability.
Polymers employed for nanoparticle fabrication have included synthetic
polymers, such as Poly (D, L-lactic-co-glycolic acid) (PLGA), polyacrylates and
polycaprolactones, and natural polymers. In particular, the application of polymer
nanoparticles in oncology has grown greatly with the advent of biodegradable
polymers. Biodegradable polymers are macromolecular materials capable of being
degraded into simpler products through chemical or enzyme-catalyzed hydrolysis in
the body. Biodegradable and biocompatible polymers as drug carriers are desirable
to minimize toxicity and avoid the requirement to surgically remove the spent
carriers. For these reasons, nanoparticles made of biodegradable materials are often
fabricated to provide sustained drug release within the target site. A good example
of a biodegradable and biocompatible polymer is PLGA, an FDA-approved
biodegradable and biocompatible polymer for biomedical applications46.
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CHAPTER 2
LITERATURE REVIEW
2.1     CANCER
Alaa Eldeen B.et al., defined that cancer is the uncontrolled growth of
abnormal cells in the body. Cancerous cells are also called malignant cells. Cancer
grows out of normal cells in the body. Normal cells multiply when the body needs
them, and die when the body doesn't need them. Cancer appears to occur when the
growth of cells in the body is out of control and cells divide too quickly. It can also
occur  when cells  forget  how to  die.  A protein  called  DNA very  carefully  controls
this growth, which is contained in genes. It is this information that allows for healing
of a wound4.
Surendrian A. et al.,  suggested  that  if  cells  in  a  body  divide  only  when
necessary and stop when the job is done the total number of cells in the adult body
will remain constant. However when a cell starts dividing and when the daughter
cells in turn keep dividing without any purpose, then the number of cells in that
particular area begins to increase and a lump appears - a cancer1.
A complex event usually involves many causal factors, which in turn are
causally linked to other factors. In talking about cause and effect, we customarily
designate as its cause one or a few salient factors most directly connected to its
salient effects, noting a few other factors as indirect causes, relegating many factors
as background conditions, and ignoring factors too vague to determine. For example,
when arson investigators decide that a fire was caused by sparks from an exposed
electric wire, they treat as background conditions the presence of oxygen and
flammable materials nearby. What made the wire exposed they regard as indirect
causes, which may interest criminal investigators. Saliency and relevancy are
context dependent
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Fig 2.1 Common sites and symptoms of cancer metastasis
Douglas and David showed that in cancer research, two scientific
approaches operate in two general kinds of context. Epidemiological focuses on
causal  factors  on  the  levels  of  people  and  population,  with  results  that  are  more
useful for disease prevention. Molecular cell biology focuses on causal mechanisms
on the levels of genes and cells,  with results that  are more useful to treatment and
cure. To biologists, factors identified by epidemiology are indirect causes in the
mechanism of cancer development. For most people, however, these factors are the
only cancer causes that they care about; they can do something about them18,20.
No treatment, conventional or otherwise, can completely eliminate all
cancer cells according to the naturally oriented physician. The reason is simple.
Cancer is a systemic disease, and there are simply too many cancerous or pro-
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cancerous cells within the ecosystem of the body. Cancer is not a localized problem
but a whole-body phenomenon of metastatic growth. Its  growth process is  affected
by biological conditions. Non-genetically based cancer forms in the body because of
toxins, the lack of oxygen poor nutrition, and other factors such as hormonal
imbalance. Whether the cancer in our body continues to multiply depends to a large
degree  on  our  body’s  biological  terrain.  It  is  this  terrain  that  determines  how  the
cancer is expressed20.
2.1.1 How cancer spreads:
Fig  2.2 Stages of tumor development
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At the center of cellular proliferation is the cell division cycle, the process
by which a cell grows, replicates its DNA and then divides to give two daughter
cells. This process is divided into four sequential phases (Figure 1.). It is often
considered that the two most important of these are S phase, when DNA replication
occurs  and  mitosis  (also  known  as  M  phase),  when  the  cell  undergoes  division  to
give two daughter cells. In fact a key concept of the cell cycle is that S phase must
always follow M phase and that M phase must not start until S phase has been
completed50. In other words, DNA replication must not commence until mitosis is
complete  and  mitosis  must  not  begin  until  the  previous  round  of  DNA  replication
has ended, thus, the integrity of the genome is maintained. In-between S and M
phase are two gaps G1 and G2. G1 follows on from mitosis and is a time during the
cell cycle when the cell is responsive to both positive and negative growth signals.
G2 is  the  gap  after  S  phase,  when the  cell  prepares  for  entry  into  mitosis.  Finally,
there  is  a  fifth  state,  G0  (also  known  as  quiescence)  into  which  the  cell  may
reversibly exit from G1, if it is deprived of the appropriate growth-promoting
signals50,51.
Figure2.3:  Cancer cell cycle
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All cancers begin in cells, the body's basic unit of life. To understand
cancer, it's helpful to know what happens when normal cells become cancer cells.
               The body is made up of many types of cells. These cells grow and divide in
a controlled way to produce more cells, as they are needed to keep the body healthy.
When cells become old or damaged, they die and are replaced with new cells.
               However according to national cancer institute U.S., sometimes this
orderly  process  goes  wrong.  The  genetic  material  (DNA)  of  a  cell  can  become
damaged or changed, producing mutations that affect normal cell growth and
division. When this happens, cells do not die when they should and new cells form
when the body does not need them. The extra cells may form a mass of tissue called
a tumor80.
               If the cells that formed the cancerous lump remained only at that site then
most cancers could be treated effectively. But cancers cells have another dangerous
feature  -  they  can  spread.  As  the  cancer  grows clumps  of  cells  will  invade  tissues
around them and later invade arteries and veins and can be carried along by them.
They could settle in another site far away from the original site. Cancers can also
travel along channels called lymphatic and spread to lymph nodes10,21.
2.1.2 Primary and secondary cancer
The site where the cancer started is called the primary cancer. The site the
cancer spreads to be called the secondary cancer.
For example a cancer may start in the breast. This is called a primary breast
cancer. It may spread to the liver and lungs. These are not new cancers in the liver
and lungs but secondaries from the primary breast cancer27.
2.1.3  Oncogenes
No one knows what it is that transforms a normal cell into a cancerous cell.
We know however that there are certain genes-oncogenes that can either promote or
Department of Pharmaceutics                        Literature Review
Annai Veilankannis Pharmacy College, Chennai
10
suppress cell division. P53 is a suppressor oncogene. In certain breast cancer tissues
excessive amounts of a defective P53 gene are present.
These cancers are generally believed to be aggressive. It may be possible in
the future to regulate growth of cancer cells by modifying these genes27.
2.1.4    The causes
Likely cause of cancer Estimated proportion ofcancer deaths (%)
Environmental
Cigarette smoking 35
Diet 2
Occupation 2
Background radiation 5
Non-environmental
Generic 5
Total 74
Unaccounted 26
Table 2.1   Causes of cancer
From the table 1.1 above we see that almost 70% of cancers are believed to
be caused by environmental factors - which mean these cancers should be
preventable. However it is not always possible to link a particular cancer causing
substance (carcinogen) and a cancer, as there is usually a long interval – latent
period - between the exposure and the cancer.
Surendrian A. et al.,  explained  many  different  kinds  of  cancers.  Cancer
can develop in almost any organ or tissue, such as the lung, colon, breast, skin,
bones, or nerve tissue1.
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There are also other causes of cancers, including:
? Benzene and other chemicals
? Drinking excess alcohol
? Environmental toxins, such as certain poisonous mushrooms and a
type of poison that can grow on peanut plants (aflatoxins)
? Excessive sunlight exposure
? Genetic problems
? Obesity
? Radiation
? Viruses
However, the cause of many cancers remains unknown.
2.1.5 Types of Cancer Classified by Body System
Cancer has the potential to affect every organ in the body. The cells within
malignant tumors have the ability to invade neighboring tissues and organs, thus
spreading the disease. It is also possible for cancerous cells to break free from the
tumor and enter the bloodstream, in turn spreading the disease to other organs. This
process of spreading is called metastasis. When cancer has metastasized and has
affected other areas of the body, the disease is still referred to the organ of
origination. For instance, if cervical cancer spreads to the lungs, it is still called
cervical cancer, not lung cancer65.
The most common types of cancer in the United States based on frequency
of diagnosis are:
? Bladder cancer
? Breast cancer
? Colon cancer
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? Endometrial cancer
? Kidney cancer (renal cell)
? Leukemia
? Lung cancer
? Melanoma
? Non-Hodgkin lymphoma
? Pancreatic cancer
? Prostate cancer
2.1.5.1 Blood Cancer
The cells in the bone marrow that give rise to red blood cells, white blood
cells, and platelets can sometimes become cancerous. These cancers are leukemia or
lymphoma65.
? Leukemia
? Lymphoma
? Multiple Myeloma
? Waldenstrom's Macroglobulinemia
2.1.5.2 Bone Cancer
Bone  cancer  is  a  relatively  rare  type  of  cancer  that  can  affect  both
children and adults, but primarily affects children and teens. There are several types
of bone cancer, but the most common types are:
? Ewing's Sarcoma
? Osteosarcoma
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2.1.5.3 Brain Cancer
Brain tumors can be malignant (cancerous) or benign (non-cancerous).
They affect both children and adults. Malignant brain tumors don't often spread
beyond the  brain.  However,  other  types  of  cancer  have  the  ability  to  spread  to  the
brain69. Types of brain cancer include:
? Adult Brain Tumor
? Brain Stem Glioma, Childhood
? Cerebellar Astrocytoma, Childhood
? Cerebral Astrocytoma/Malignant Glioma, Childhood
? Ependymoma, Childhood
? Medulloblastoma, Childhood
? Supratentorial Primitive Neuroectodermal Tumors and Pineoblastoma,
Childhood
? Visual Pathway and Hypothalamic Glioma, Childhood.
2.1.5.4 Breast Cancer
Breast cancer is a common type of cancer that affects women and much
less commonly, men. More than 200,000 women are diagnosed with breast cancer in
the United States each year65. Types of breast cancer include, but are not limited to:
? Ductal carcinoma in situ
? Lobular carcinoma in situ
? Inflammatory breast cancer
? Paget's disease of the nipple
? Invasive types of breast cancer
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2.1.5.5 Digestive/Gastrointestinal Cancers
This is a broad category of cancer that affects everything from the
esophagus to the anus. Each type is specific and has its own symptoms, causes, and
treatments69.
? Anal Cancer
? Bile Duct Cancer, Extrahepatic
? Carcinoid Tumor, Gastrointestinal
? Colon Cancer
? Esophageal Cancer
? Gallbladder Cancer
? Liver Cancer, Adult Primary
? Liver Cancer, Childhood
? Pancreatic Cancer
? Rectal Cancer
? Small Intestine Cancer
? Stomach (Gastric) Cancer
2.1.5.6 Endocrine Cancers
The endocrine system is an instrumental part of the body that is responsible
for glandular and hormonal activity. Thyroid cancer is the most common of the
endocrine cancer types and generally, the least fatal65.
? Adrenocortical Carcinoma
? Carcinoid Tumor, Gastrointestinal
? Islet Cell Carcinoma (Endocrine Pancreas)
? Parathyroid Cancer
? Pheochromocytoma
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? Pituitary Tumor
? Thyroid Cancer
2.1.5.7 Eye Cancer
Like other organs in the human body, the eyes are vulnerable to    cancer as
well. Eye cancer can affect both children and adults.
? Melanoma, Intraocular
? Retinoblastoma
2.1.5.8 Genitourinary Cancers
These types of cancer affect the male genitalia and urinary tract65.
? Bladder Cancer
? Kidney (Renal Cell) Cancer
? Penile Cancer
? Prostate Cancer
? Renal Pelvis and Ureter Cancer, Transitional Cell
? Testicular Cancer
? Urethral Cancer
? Wilms' Tumor and Other Childhood Kidney Tumors
2.1.5.9 Gynecologic Cancers
This group of cancer types affects the organs of the   female reproductive
system. Specialized oncologists called gynecologic oncologists are recommended
for treating gynecologic cancer.
? Cervical Cancer
? Endometrial Cancer
? Gestational Trophoblastic Tumor
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? Ovarian Cancer
? Uterine Sarcoma
? Vaginal Cancer
2.1.5.10 Head and Neck Cancer
Most head and neck cancers affect moist mucosal  surfaces of the head and
neck, like the mouth, throat, and nose. Causes of head and neck cancer vary, but
cigarette smoking plays a role. Current research suggests a strong HPV link in the
development of some head and neck cancer69.
? Hypopharyngeal Cancer
? Laryngeal Cancer
? Lip and Oral Cancer
? Metastatic Squamous Neck Cancer
? Nasopharyngeal Cancer
? Oropharyngeal Cancer
? Paranasal Sinus and Nasal Cavity Cancer
? Parathyroid Cancer
? Salivary Gland Cancer
2.1.5.11 Respiratory Cancers
Cigarette smoking is the primary cause for cancer affecting the respiratory
system. Exposure to asbestos is also a factor65.
? Lung Cancer, Non-Small Cell
? Lung Cancer, Small Cell
? Malignant Mesothelioma
? Thymoma and Thymic Carcinoma
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2.1.6    Diagnosis
To confirm a diagnosis of cancer it is almost always necessary to remove a
small piece of the tumor for examination; this is called a biopsy. The presence in the
blood of certain proteins called tumor markers (e.g. C.E.A., CA-125, P.S.A. etc.)
may point to a diagnosis of cancer but are never enough in themselves to establish
the diagnosis. Once the diagnosis is made, it may be necessary to carry out further
tests such as CT Scans, Bone marrow studies etc. to see if there is evidence of
spread of cancer. This is called staging13.
2.1.7    Treatment
Treatment of cancer is by surgery, radiotherapy and chemotherapy.
2.1.7.1   Surgery
In cancer surgery is used
1)  To make the diagnosis
2)  To remove all the tumor or most of the tumor
3)  To control symptoms even when a cancer is too advanced to be cured
e.g. removing a tumor that is causing severe bowel obstruction and
lastly
4)  To prevent cancers by removing an organ when the risk of malignant
transformation is very high.
2.1.7.2  Radiotherapy
This is the use of x-rays to treat cancers. Some cancers are curable by
radiotherapy e.g. cancers of the cervix. It is also used to mop up the tumor area after
surgery. In incurable cancers radiotherapy can provide relief from pain caused by
spread to the bones13.
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2.1.7.3 Chemotherapy
This involves the use of drugs to destroy cancer cells.                   Some
cancers are curable by chemotherapy e.g. certain lymphomas. In certain cancers
especially breast and colon cancers chemotherapy is used in addition to surgery and
radiotherapy to prevent spread of the cancers13.
2.2 ROLE OF NANOTECHNOLOGY IN CANCER THERAPY
Ferrai  M. explained that the nanomedicine involves utilization of
nanotechnology for the benefit of human health and well being. The use of
nanotechnology in various sectors of therapeutics has revolutionized the field of
medicine where nanoparticles of dimensions ranging between 1 - 100 nm are
designed and used for diagnostics, therapeutics and as biomedical tools for research.
It is now possible to provide therapy at a molecular level with the help of these tools,
thus treating the disease and assisting in study of the pathogenesis of disease22.
Conventional drugs suffer from major limitations of adverse effects occurring as a
result of non-specificity of drug action and lack of efficacy due to improper or
ineffective dosage formulation (e.g., cancer chemotherapy and antidiabetic agents).
Designing of drugs with greater degree of cell specificity improves efficacy and
minimizes adverse effects. Diagnostic methods with greater degree of sensitivity aid
in early detection of the disease and provide better prognosis. Nanotechnology is
being applied extensively to provide targeted drug therapy, diagnostics, tissue
regeneration, cell culture, biosensors and other tools in the field of molecular
biology. Various nanotechnology platforms like fullerenes, nanotubes, quantum
dots, nanopores, dendrimers, liposomes, magnetic nanoprobes and radio controlled
nanoparticles are being developed10.
2.2.1 Current status of therapeutics
The major factors influencing the treatment outcome in a patient are the
efficacy and safety profile of the drug more so when used for cancer chemotherapy.
These drugs have poor cell specificity and high toxicity like bone marrow
suppression, gastric erosion, hair loss, renal toxicity, cardiomyopathy, and several
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effects on other systems. Similarly treatment for diabetes faces challenges with the
route of delivery and inadequate glycaemic control. Availability of non-parenteral
dosage forms of insulin would be a breakthrough and development of a suitable drug
delivery device can aid in this approach. In many cases, the sensitivity and
specificity of various diagnostic methods as in radio imaging and various assays for
detection of malignancy are not sufficient enough for early detection and treatment1.
2.2.2 Liposomes
Liposomes discovered in mid 1960s were the original models of
nanoscaled drug delivery devices. They are spherical nanoparticles made of lipid
bilayer membranes with an aqueous interior but can be unilamellar with a single
lamella of membrane or multilamellar with multiple membranes. They can be used
as effective drug delivery systems. Cancer chemotherapeutic drugs and other toxic
drugs like amphotericin and hamycin, when used as liposomal drugs produce much
better efficacy and safety as compared to conventional preparations. These
liposomes can be loaded with drugs either in the aqueous compartment or in the
lipid membrane. Usually water-soluble drugs are loaded in aqueous compartment
and lipid soluble drugs are incorporated in the liposomal membrane73,74. The major
limitation of liposome is its rapid degradation and clearance by the liver
macrophages, thus reducing the duration of action of the drug it carries. This can be
reduced to a certain extent with the advent of stealth liposomes where the liposomes
are coated with materials like polyoxyethylene that prevents opsonisation of the
liposome and their uptake by macrophages. Other ways of prolonging the circulation
time of liposomes are incorporation of substances like cholesterol,
polyvinylpyrollidone polyacrylamide lipids and high transition temperature
phospholipids distearoyl phosphatidylcholine74.
Targeting of liposomal drugs:
Liposomes can be targeted to specific organ or tissue by passive as well as
active methods. As the liposomal drug acts minimally on other tissues, the safety
profile is better than non-liposomal drug. The vascularity in tumour tissue is poorly
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organized and significant leak occurs from blood vessel in the tumour tissue. The
liposomal drugs get accumulated in the tumour tissue passively and produce
enhanced effects. Active targeting of the drug can be achieved by using
immunoliposomes and ligand directed liposomes.
Sapra P. et al suggested that immunoliposomes are liposomes conjugated
with  an  antibody  directed  towards  the  tumour  antigen.  The  antibody  can  be
conjugated to the surface of a stealth liposome, the polyoxyethylene coating of a
stealth liposome or on the surface of a non-stealth liposome. These
immunoliposomes when injected into the body, reaches the target tissue and gets
accumulated in its site of action. This reduces unwanted effects and also increases
the drug delivery to the target tissue, thus enhancing its safety and efficacy73.
Antibody directed enzyme prodrug therapy (ADEPT) consists of liposomes
conjugated with an enzyme to activate a prodrug and an antibody directed to a
tumour antigen (enzyme linked immunoliposomes). These are administered prior to
administration of a prodrug. The antibody directs the enzyme to the target tissue
where it activates the prodrug selectively and converts it to its active form. This
way, action of the drug is avoided in other normal tissues, thus minimizing the
toxicity of drug.
Such studies are being tried with epirubicin and doxorubicin. Ligand
bearing liposomes are conjugated with specific ligands, which are directed towards
target structures. In ovarian cancer, over expression of folate receptors by the
tumour tissue occurs. The liposomal drug can be conjugated with folate so as to
direct the molecule to the tumour. This method is also being tried in the treatment of
leishmaniasis where liposomal hamycin conjugated with mannosyl human serum
albumin are targeted towards human macrophages. Asialofeutin conjugation is being
tried to target liver cells for gene therapy. The targeted liposomal preparations are
found to have a better efficacy than non-targeted liposomes73,74.
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2.2.3 Polymeric Nanoparticles
To reach the targeted tumor tissue, nanoparticles must be able to stay in the
bloodstream for considerable lengths of time without being eliminated.
Nanoparticles with no surface modification are usually caught by the MPS,
primarily the liver and spleen, during circulation, depending on their size and
surface characteristics. To overcome this problem, nanoparticles can be coated with
hydrophilic polymers. Coating can efficiently protect nanoparticles from capture by
macrophages. The increased hydration also helps nanoparticles to be more water
soluble and less sensitive to enzymatic degradation, therefore enhancing
biocompatibility.
During the past decade, the application of polymer-based drug delivery
systems in oncology has grown exponentially with the advent of biodegradable
polymers. In these polymers, drugs are either physically dissolved, entrapped,
encapsulated, or covalently attached to the polymer matrix. The resulting
compounds may have different structures, including micelles and dendrimers. Both
natural (albumin, chitosan, heparin, etc.) and synthetic (poly-L-lactide, poly-
[Lglutamate], poly-[D,L-lactide-co-glycolide], PEG, etc.) biodegradable polymers
are being exploited as drug delivery system92.
Recently, a nanoparticle formulation of paclitaxel bound to albumin
(Abraxane or ABI-007) was approved for the treatment of metastatic breast cancer.
In a Phase III clinical trial, ABI-007 showed greater therapeutic efficacy and
increased response compared with free paclitaxel. Currently, more than 10
formulations of anticancer polymeric nanoparticles have entered clinical
development, including paclitaxel poliglumex (Xyotax), N- (2-hydroxypropyl)
methacrylamide (HPMA) copolymer-camptothecin (MAG-CPT), and HPMA-DOX
(PK1).  In Phase I/II  clinical  trials,  HPMA-DOX showed a 4 to 5-fold reduction in
anthracycline-related toxicity. At DOX equivalent doses of 80 to 320 mg/m2, the
drug still displayed significant antitumor activity in chemotherapy-refractory
patients  (including  those  with  breast  cancer).  A  recent  Phase  III  trial  showed  that
paclitaxel poliglumex (Xyotax) was less toxic than free paclitaxel and could prolong
the survival of non-small-cell lung cancer patients with poor performance status.
Also, paclitaxel poliglumex can be used as a novel radiation sensitizer89.
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2.2.4       Targeting mechanism
In principal, nanoparticle delivery of anticancer drugs to tumor tissues can
be achieved by either passive or active targeting.
2.2.4.1  Passive Targeting
Passive targeting takes advantage of the inherent size of nanoparticles and
the unique properties of tumor vasculature, such as the enhanced permeability and
retention (EPR) effect and the tumor microenvironment. This approach can
effectively enhance drug bioavailability and efficacy.
EPR Effect: Angiogenesis is crucial to tumor progression. Angiogenic blood
vessels in tumor tissues, unlike those in normal tissues, have gaps as large as 600 to
800 nm between adjacent endothelial cells. This defective vascular architecture
coupled with poor lymphatic drainage induces the EPR effect, which allows
nanoparticles to extravasate through these gaps into extravascular spaces and
accumulate inside tumor tissues. Dramatic increases in tumor drug accumulation,
usually of 10-fold or greater, can be achieved when a drug is delivered by a
nanoparticle rather than as a free drug.
However, the localization of nanoparticles within the tumor is not
homogeneous. The factors that result in high concentrations of nanoparticles in one
part of the tumor tissue but not in other parts are not well understood yet. In general,
the accumulation of nanoparticles in tumors depends on factors including the size,
surface characteristics, and circulation half-life of the nanoparticle and the degree of
angiogenesis of the tumor. Usually, less nanoparticle accumulation is seen in
preangiogenic or necrotic tumors71.
Although PLGA represents the ‘gold standard’ (exemplified by more than
500 patents) of biodegradable polymers, increased local acidity because of
degradation can lead to irritation at the site of polymer application. Further, the
increased local acidity may also be detrimental to the stability of protein drugs62.
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Tumor Microenvironment
Hyperproliferative cancer cells have profound effects on their surrounding
microenvironment. Tumors must adapt to use glycolysis (hypoxic metabolism) to
obtain extra energy, resulting in an acidic microenvironment. In addition, cancer
cells overexpress and release some enzymes that are crucial to tumor migration,
invasion, and metastasis, including matrix metalloproteinases (MMPs).
Tumoractivated prodrug therapy is an example of passive targeting that takes
advantage of this characteristic of the tumor-associated microenvironment. A
nanoparticle conjugating an albumin-bound form of DOX with an MMP-2–specific
peptide sequence (Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln) was efficiently and
specifically cleaved by MMP- 2. When certain pH-sensitive molecules are
incorporated into liposomes, drugs can be specifically released from the complexes
by a change in pH.9. The pH-sensitive liposomes are stable at physiologic
conditions (pH 7.2), but degraded in tumor-associated acidic areas.
Fig 2.4: Passive Tumor Targeting with Nanoparticle Drugs. Long-circulating
therapeutic nanoparticles accumulate passively in solid tumor tissue
by the enhanced permeability and retention effect. The hyperpermeable
angiogenic tumor vasculature allows preferential extravasation of
circulating nanoparticles.
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Likewise, thermolabile liposomes were expected to be activated by the
local hyperthermic microenvironment71.
Fig 2.5  Internalization of Nanoparticles via Receptor-mediated Endocytosis.
Nanoparticle-conjugated tumor-specific ligands/antibodies bind to
surface receptors, triggering nanoparticle internalization through an
endosome-dependent mechanism. As the interior of the endosome
becomes more acidic, drugs are released from the nanoparticle into the
cytoplasm.
2.2.4.2  Active Targeting
The polymeric nanoparticles that have been tested clinically so far have
mostly lacked a targeting moiety and instead rely mainly on the EPR effect of
tumors, the tumor microenvironment, and tumor angiogenesis to promote some
tumorselective delivery of nanoparticles to tumor tissues.
However, these drug delivery systems using a binary structure conjugate
inevitably have intrinsic limitations to the degree of targeting specificity they can
achieve.  In  the  case  of  the  EPR  effect,  while  poor  lymphatic  drainage  on  the  one
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hand helps the extravasated drugs to be enriched in the tumor interstitium, on the
other hand, it induces drug outflow from the cells as a result of higher osmotic
pressure in the interstitium, which eventually leads to drug redistribution in some
portions of the cancer tissue73.
Garrett explained an alternative strategy to overcome these limitations is to
conjugate a targeting ligand or an antibody to nanoparticles. By incorporating a
targeting molecule that specifically binds an antigen or receptor that is either
uniquely expressed or overexpressed on the tumor cell surface, the ligand-targeted
approach is expected to selectively deliver drugs to tumor tissues with greater
efficiency (Figure 2). Such targeted nanoparticles may constitute the next generation
of polymeric nanoparticle drug delivery systems. Indeed, several targeted polymeric
nanoparticles are currently undergoing preclinical studies16.
2.2.4.2.1 Choice of Target Receptor
Selection of the appropriate receptor or antigen on cancer cells is crucial
for the optimal design of targeted nanoparticles. The ideal targets are those that are
abundantly and uniquely expressed on tumor cells, but have negligible or low
expression on normal cells. The targeted antigen or receptor should also have a high
density on the surface of the target tumor cells. Whether the targeted nanoconjugate
can be internalized after binding to the target cell is another important criterion in
the selection of proper targeting ligands. In the case of an antibody or other ligand
that cannot trigger the internalization process, the drug can enter cells through
simple diffusion or other transport system after being released from the targeted
conjugate at or near the cell surface63. However, drug released outside the cell may
disperse or redistribute to the surrounding normal tissues rather than exclusively to
the cancer cells. In vitro and in vivo comparisons using internalizing or noninternalizing
ligands have shown that the intracellular concentration of drug is much higher when
the drug is released from nanoparticles in the cytoplasm after internalization74.
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2.2.4.2.2 Choice of Targeting Ligand
One of the greatest challenges to the design of nanoparticles that can
selectively and successfully transport drug to cancerous tissues is the choice of
targeting  agent(s).  This  strategy  also  relies  on  the  ability  of  the  targeting  agent  or
ligand to bind the tumor cell surface in an appropriate manner to trigger receptor-
mediated endocytosis. The therapeutic agent will thereby be delivered to the interior
of the cancer cell. A variety of tumor targeting ligands, such as antibodies, growth
factors, or cytokines, have been used to facilitate the uptake of carriers into target51.
Ligands targeting cell-surface receptors can be natural materials like folate
and growth factors, which have the advantages of lower molecular weight and lower
immunogenicity  than  antibodies.  However,  some  ligands,  such  as  folate  that  is
supplied by food, show naturally high concentrations in the human body and may
compete with the nanoparticle-conjugated ligand for binding to the receptor,
effectively reducing the intracellular concentration of delivered drug.
Recent advances in molecular biology and genetic engineering allow
modified antibodies to be used as targeting moieties in an active-targeting approach.
MAbs or antibody fragments (such as antigen-binding fragments or single-chain
variable fragments) are the most frequently used ligands for targeted therapies.
Whole mAbs have 2 binding domains showing high binding avidity. The Fc domain
of the mAb can induce complement-mediated cytotoxicity and antibody- dependent,
cell-mediated cytotoxicity, leading to additional cell-killing effect. On the other
hand, the Fc domain also initiates an immune response and can be rapidly eliminated
in the circulation, resulting in decreased accumulation of targeted nanoparticles into
cancer cells51.
Compared with whole mAbs, the use of antibody fragments as a targeting
moiety can reduce immunogenicity and improve the pharmacokinetic profiles of
nanoparticles. For example, liposomes coupled with mAb fragments instead of
whole antibodies showed decreased clearance rates and increased circulation half-
lives, allowing the liposomes sufficient time to be distributed and bind to the
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targeted cells. This strategy improved the therapeutic efficacy of immunoliposomal
DOX targeted against CD19 on human B lymphoma cells in animal models.
2.2.4.2.3 Tumor extra cellular pH targeting:
Tumor-targeting approaches have been developed for improved efficacy
and reduced toxicity by altering biodistribution of cancer drugs and by using specific
cell surface interactions. Solid tumors are often characterized by over expression of
specific antigens or receptors on cell surfaces and Antigens and receptors help in
transmitting signals from the surrounding environment that are essential for the
growth of tumor cells. Targeting antigens or receptors has been extensively
investigated as an important delivery mode by using macromolecular or nano-sized
carriers to tumor cells. Nanodrug carriers attached with surface ligands or antibodies
exploit these receptor-mediated uptake pathways that are recognized and
internalized by the tumor cells85.
However, these approaches have achieved limited success in clinic, most
likely because of significant heterogeneity in both solid tumor cell types and cell
surface markers [8] N. Scholler, N. Fu, Y. Yang, Z. Ye, G.E. Goodman, K.E.
Hellstrom and I. Hellstom, Soluble member(s) of the mesothelin/megakaryocyte
potentiating factor family are detectable in sera from patients with ovarian
carcinoma, Proc. Natl. Acad. Sci. U. S. A. 96 (1999), pp. 11531–11536. Full Text
via CrossRef | View Record in Scopus | Cited By in Scopus (140). Additionally,
both  the  presence  of  antigens  and  the  expression  of  receptors  on  surface  of  these
tumor cells are transient and dynamic. The heterogeneity of cancer cells may explain
the reasons for the unexpected results of targeting strategy6.81.
The extracellular pH (pHe) of normal tissues and blood pH are kept
constant at pH 7.4 and their intracellular pH (pHi) at 7.2. However, in most tumors
the pH gradient is reversed (pHi > pHe). Particularly, tumor pHe is lower than normal
tissues. Although there is a distribution in in vivo, pHe measurements made by using
needle type microelectrodes on human patients having various solid tumors
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(adenocarcinoma, squamous cell carcinoma, soft tissue sarcoma, and malignant
melanoma) and in readily accessible areas (limbs, neck, or chest wall), shows the
mean pH value to be 7.0 with a range between 5.7 and 7.8.
This variation is dependent upon tumor histology, tumor volume, and
location inside a tumor81.  Recent  measurements  of  pHe by noninvasive technology
such as 19F, 31P, or 1H probes by magnetic resonance spectroscopy in human tumor
xenografts and in animals further proved consistently low pHe. Reported pHe data on
human and animal solid tumors either by invasive or noninvasive methods showed
that more than 80% of all measured values are below pH 7.2. The primary reason for
this imbalance in cancer pH is the high rate of glycolysis in cancer cells, both in
aerobic and anaerobic conditions. It is also proposed that the acidic milieu benefits
the cancer cells by generating an invasive environment that tears down the
extracellular matrix and destroys the surrounding normal tissue cells54.
There are a variety of mechanisms associated with MDR cells that need to
be circumvented for a successful tumor treatment. At unicellular level, ATP
dependent drug-efflux pumps of P-glycoprotein (Pgp), multidrug resistance protein
(MRP), lung resistance protein (LRP), antiapototic (or survival) bcl-2 gene, and
altered expression of Topoisomerase II interfere with a sufficient intracellular drug
dose and decrease the effectiveness of drug in killing tumor cell. In clinical setting,
additional tumor microenvironmental factors such as epidermal growth factor,
fibroblast growth factor, insulin-like growth factor, and extracellular matrix
components are strongly associated with survival mechanisms of cancer cells under
cytotoxic drug treatment51.
To tackle themultifacetedMDRmechanisms, it is hypothesized that a focal
high dose strategy works at  cellular level rather than at  systemic level.  In addition,
local high dose may overwhelm most resistant mechanisms, which might have their
intrinsic limitation in defense capability because even extremely resistant
experimentalMDR cells are killed at high drug concentrations. Intracellular
organelles in parental drug-sensitive cells are characterized to have somewhat acidic,
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diffuse pH profiles inside cells54. MDR cancer cells develop more acidic organelles
(recycling endosome and lysosome) than those in sensitive cells, which are more
acidic than cytosolic pH and nucleoplasmic pH. This results in acid-induced
sequestration of anticancer drugs. Acidic organelles in MDR cells contribute to
developing resistance to chemotherapeutic drugs.
Since most anticancer drugs are in an ionizable form, the pH of
extracellular matrix and intracellular compartments are critical factors in
determining drug partitioning and distribution. The low pH in tumor extracellular
space or in various subcellular organelles is a significant signal for targeting89.
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CHAPTER 3
AIM AND OBJECTIVE
Nanomedicine involves utilization of nanotechnology for the benefit of
human health and well being. The use of nanotechnology in various sectors of
therapeutics has revolutionized the field of medicine where nanoparticles of
dimensions ranging between 1 - 100 nm are designed and used for diagnostics,
therapeutics and as biomedical tools for research1. It is now possible to provide
therapy at a molecular level with the help of these tools, thus treating the disease and
assisting in study of the pathogenesis of disease44.
The  present  work  was  carried  out  to  develop  a  PLGA  based
nanoparticulate drug delivery system for an anticancer drug irinotecan hydrochloride
trihydrate (IRN) for effecient tumor targeting.
The main objectives of this work are as follows:
a) Analytical method development
b)  Formulation and optimization of IRN loaded PLGA nanoparticles.
c) Charaterization of IRN loaded PLGA nanoparticles.
d) In vitro drug release study.
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CHAPTER 4
DRUG AND POLYMER PROFILE
4.1 DRUG PROFILE
4.1.1   Chemical name
Irinotecan hydrochloride trihydrate
4.1.2 Molecular structure
Figure 4.1: Molecular structure of IRN
4.1.3     Molecular formula
C33H38N4O6.HCl.3 (H2O)
4.1.4 IUPAC Name
(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo
[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-
yl4-(piperidin-1-yl)piperidine-1-carboxylate39,36.
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4.1.5     Melting Point
222-223 oC
4.1.6    Molecular weight
586.6780
4.1.7  Solubility
Water soluble (1.07 g/ml)
4.1.8 Categories
Antineoplastic Agents
? Radiation-Sensitizing Agents
? Parasympathomimetics
? Enzyme Inhibitors
? Prodrugs
? Antineoplastic Agents, Phytogenic
4.1.9  Mechanism of action
Irinotecan inhibits the action of topoisomerase I. Irinotecan prevents
religation of the DNA strand by binding to topoisomerase I-DNA complex. The
formation of this ternary complex interferes with the moving replication fork, which
induces replication arrest and lethal double-stranded breaks in DNA. As a result, DNA
damage is not efficiently repaired and apoptosis (programmed cell death) occurs39.
4.1.10  Pharmacology
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the
treatment of colorectal cancer. Irinotecan is a semisynthetic derivative of
camptothecin. Camptothecins interact specifically with topoisomerase I, an enzyme
in the cell nucleus that regulates DNA topology and facilitates nuclear processes
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such  as  DNA  replication,  recombination,  and  repair.  During  these  processes,
topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand
breaks, allowing single DNA strands to pass through the break. The 3'-DNA
terminus of the broken DNA strands bind covalently with the topoisomerase enzyme
to form a catalytic intermediate called a cleavable complex.
After the DNA is sufficiently relaxed and the strand passage reaction is
complete, DNA topoisomerase reattaches the broken DNA strands to form the
chemically unaltered topoisomers that allow transcription to proceed. Irinotecan and
its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent
religation of these single-strand breaks. Current research suggests that the
cytotoxicity of irinotecan is due to double-strand DNA damage produced during
DNA synthesis when replication enzymes interact with the ternary complex formed
by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot
efficiently repair these double-strand breaks. The precise contribution of SN-38 to
the activity of irinotecan in humans is not known. Irinotecan is cell cycle phase-
specific (S-phase)37.
4.1.11  Indication
For the treatment of metastatic colorectal cancer (first-line therapy when
administered with 5-fluorouracil and leucovorin). Also used in combination with
cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently
under investigation for the treatment of metastatic or recurrent cervical cancer.
4.1.12  Protein binding
30%-68%
4.1.13  Route of elimination
The cumulative biliary and urinary excretion of irinotecan and its
metabolites (SN-38 and SN-38 glucuronide) over a period of 48 hours following
administration of irinotecan in two patients ranged from approximately 25% (100
mg/m2) to 50% (300 mg/m2)39.
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4.1.14 Half-life
6-12 hours
4.1.15  Toxicity
Gastrointestinal complications, such as nausea, vomiting, abdominal
cramping, diarrhea, and infection.
4.2         POLYMER PROFILE
PLGA is a synthetic copolymer of lactic acid and glycolic acid and is one
of the most widely used FDA-approved biodegradable polymers for controlled
release drug delivery systems. PLGA or poly(lactic-co-glycolic acid) is  a
copolymer which is used in a host of Food and Drug Administration (FDA)
approved therapeutic devices, owing to its biodegradability and biocompatibility.
PLGA is synthesized by means of random ring-opening co-polymerization of two
different monomers, the cyclic dimers (1,4-dioxane-2,5-diones) of glycolic acid and
lactic acid. Common catalysts used in the preparation of this polymer include tin(II)
2-ethylhexanoate, tin(II) alkoxides, or aluminum isopropoxide. During
polymerization, successive monomeric units (of glycolic or lactic acid) are linked
together in PLGA by ester linkages, thus yielding a linear, aliphatic polyester as a
product7,86.
               Depending on the ratio of lactide to glycolide used for the polymerization,
different forms of PLGA can be obtained: these are usually identified in regard to
the monomers' ratio used (e.g. PLGA 75:25 identifies a copolymer whose
composition is 75% lactic acid and 25% glycolic acid). All PLGAs are amorphous
rather than crystalline and show a glass transition temperature in the range of 40-60
°C. Unlike the homopolymers of lactic acid (polylactide) and glycolic acid
(polyglycolide) which show poor solubilities, PLGA can be dissolved by a wide
range of common solvents, including chlorinated solvents, tetrahydrofuran, acetone
or ethyl acetate7.
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PLGA degrades by hydrolysis of its ester linkages in the presence of water.
It has been shown that the time required for degradation of PLGA is related to the
monomers'  ratio  used  in  production:  the  higher  the  content  of  glycolide  units,  the
lower the time required for degradation. An exception to this rule is the copolymer
with 50:50 monomers' ratio which exhibits the faster degradation (about two
months). In addition, polymers that are end-capped with esters (as opposed to the
free carboxylic acid) demonstrate longer degradation half-lives.
PLGA has been successful as a biodegradable polymer because it
undergoes hydrolysis in the body to produce the original monomers, lactic acid and
glycolic acid. These two monomers under normal physiological conditions, are by-
products of various metabolic pathways in the body. Since the body effectively deals
with the two monomers, there is very minimal systemic toxicity associated with
using PLGA for drug delivery or biomaterial applications. Also, the possibility to
tailor the polymer degradation time by altering the ratio of the monomers used
during synthesis has made PLGA a common choice in the production of a variety of
biomedical devices such as: grafts, sutures, implants, prosthetic devices, micro and
nanoparticles. It has also been used successfully in delivery Amoxicillin in treating
listeriosis (treatment of Listeria monocytogenes infection)[2] As an example, a
commercially available drug delivery device using PLGA is Lupron Depot? for the
treatment of advanced prostate cancer66.
The biodegradation of PLGA occurs through a hydrolytic chain cleavage
mechanism. In vivo, PLGA undergoes chemical hydrolysis as well as enzymatic
cleavage of its backbone ester linkages to form the biologically compatible moieties,
lactic acid and glycolic acid. The degradation products are subsequently eliminated
from the body as carbon dioxide and water by the tricarboxylic acid cycle. The
chemical structure of PLGA is illustrated in Figure , where “m” and “n” refer to the
relative amounts of lactide and glycolide units, respectively, in a specific PLGA
copolymer. The composition of PLGA can be varied by modifying the chain length
(molecular weight), as well as the ratio of lactic to glycolic acid monomers in the
polymer chain. This flexibility of composition is advantageous as it can be
Department of Pharmaceutics           Drug and polymer profile
Annai Veilankannis Pharmacy College, Chennai
36
manipulated to yield appropriate physical properties for a particular application. For
example, the in vivo degradation rate of PLGA can be tailored by controlling the
ratio of “m” and “n”, with slower degradation rates observed for polymers with
higher m/n ratios56.
Although a number of different polymers have been investigated for
formulating biodegradable nanoparticles, poly (l-lactic-acid) (PLA) and its
copolymers with glycolic acid (PLGA) have been extensively used for controlled
drug delivery systems63,57. The lactide/glycolide polymers chains are cleaved by
hydrolysis into natural metabolites (lactic and glycolic acids), which are eliminated
from the body by the citric acid cycle. PLGA provides a wide range of degradation
rates, from months to years, depending on its composition and molecular weight43,57.
PLGA has a long history of safe use as surgical sutures and implants, and it
is applied in at least 12 different marketed products from 10 different companies
worldwide. PLGA is used not only as a resorbable suture material and a scaffold for
tissue engineering, but also in drug delivery. PLGA delivery platforms have been
developed for the sustained and targeted delivery of plasmid DNA; recombinant
HIV envelope (env) protein (Moore et al., 1995); hormones (Sun et al., 2008) and
anticancer agents. PLGA nanoparticles have been formulated as colloidal carrier
systems to improve drug efficacy21,22. Drug  release  from  PLGA  nanoparticles  is
controllable through the rate of drug diffusion in the polymer matrix and/or
degradation of the polymer matrix.
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Figure 4.2: PLGA molecular structure
4.2.1  Method of Preparation
Preparation of nanoparticles is frequently based on the use of dispersed
systems in which solid or liquid phases are dispersed in fluid media to constitute
embryos of the final particles. Single and multiple emulsion systems have been used
to encapsulate drugs into polymeric particles. Normally, an organic solvent is
required to dissolve the polymers in the emulsion step. To decrease droplet size and
avoid droplet coalescence, surfactants are usually required56.
Techniques for preparing PLGA nanoparticles may be divided into bottom-
up and top-down approaches. The bottom-up techniques, which include emulsion or
microemulsion polymerization, interfacial polymerization and precipitation
polymerization, employ the monomers as a starting point, and nanoparticle
fabrication occurs simultaneously with monomer polymerization into PLGA. Top-
down techniques include the emulsion evaporation, emulsion diffusion, solvent
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displacement and salting out methods in which nanoparticles are prepared from
preformed PLGA.
Of  the  techniques  reported,  emulsion  evaporation  and  emulsion  diffusion
are the two most frequently employed. In the emulsion diffusion method, the PLGA
polymer is dissolved in an organic phase which is partially miscible in water, and the
organic phase is emulsified with an aqueous surfactant solution under stirring or
sonication67.
Diffusion of the organic solvent and the counter diffusion of water into the
emulsion droplets induce polymer nanoparticle formation. The emulsion evaporation
method is similarly based on emulsification principles, except that the organic
solvent for dissolving the polymer/drug is highly volatile, and is evaporated off
following emulsification. Examples of appropriate solvents include ethyl acetate,
chloroform and methylene chloride. Like the emulsion diffusion method, the
aqueous phase also contains a dissolved surfactant to impart stability, and
emulsification is carried out under high-shear stress to reduce the size of the
emulsion droplet. Important parameters in emulsion evaporation method that may
affect nanoparticle size are: PLGA co-polymer ratio, polymer concentration, solvent
characteristics, surfactant/polymer molecular mass, viscosity, phase volume ratios,
stirring rate, and temperature87,7.
4.2.2  Applications
Biodegradable nanoparticles formulated from PLGA have been widely
investigated for sustained and targeted delivery of therapeutic agents, including
plasmid DNA, proteins, and low molecular weight compounds. Encapsulation in
PLGA nanoparticles could protect susceptible protein therapeutic agents from
physical denaturation and chemical degradation, thereby lengthening their half-life.
The administration route for the proteins can also be changed from injection, which
is invasive and associated with poor patient compliance, to a more acceptable non-
invasive route. PLGA nanoparticles are also extensively applied for the delivery of
anticancer agents due to their capacity to enhance drug efficacy by regulating the
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drug release rate, improving drug stability and prolonging drug circulation time in
vivo. Incorporation of anticancer agents in nanoparticles has been shown to result in
a more favorable circulation half-life, area under the concentration-time curve
(AUC) and peak plasma concentration86,14,45.
An example is the paclitaxel-loaded PLGA nanoparticles, which not only
reduced the dose and frequency of administration of paclitaxel, but also provided
improved targeting of the drug to cancer cells. Other anticancer agents investigated
with PLGA nanoparticles included doxorubicin, camptothecin and 5-fluorouracil.
Nevertheless, PLGA nanoparticles are not without shortcomings, one of which is
their non-site specific targeting capability. Another is the rapid removal of the naked
PLGA nanoparticles from the bloodstream by the RES system. Complete clearance
takes only a matter of minutes, with most of the nanoparticle dose concentrating in
the  liver  and  spleen.  Several  approaches  to  improve  the  selectivity  of  the  delivery
system have been investigated, the most common of which is the application of
nanoparticles conjugated with targeting ligands. Ligand conjugation allows the
specific delivery of the drug load to cancer cells, which not only increases
therapeutic efficacy, but also reduces side effects associated with non-discriminatory
drug deposition.
In one study, monoclonal antibody (mAb)-modified PLGA nanoparticles
were shown more likely to be bound to the targeted invasive epithelial breast tumor
cells than non-coated nanoparticles92. PLGA nanoparticles functionalized with the
A10 RNA aptamer also resulted in enhanced nanoparticle delivery to the prostate
tumor in the xenograft mouse model compared to equivalent non-conjugated
nanoparticles. In yet another study, PLGA nanoparticles conjugated with poly (L-
lysine)-poly (ethylene glycol)-folate were observed to improve cellular uptake of the
nanoparticles into the folate receptor over-expressing KB cells by folate receptor-
mediated endocytosis. A few PLGA-based drug delivery formulations have been in
use in the clinic. Lupron Depot, an injectable suspension formulation of leuprolide
acetate-loaded PLGA microspheres, is the first peptide formulation for the treatment
of  advanced  prostate  cancer.  Peptide  release  occurs  over  a  period  of  1,  3  or  4
months, and is governed mainly by the PLGA degradation rate. Nutropin DepotTM
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is another PLGA microsphere formulation, and the FDA has approved it in late 1999
for the treatment of pediatric growth hormone deficiency. Consisting of micronized
particles of recombinant human growth hormone (rhGH) embedded in a PLGA
matrix, this formulation requires only one or two doses a month compared to the
conventional therapy that requires multiple doses per week. There are as yet no
PLGA nanoparticle-based drug delivery formulations in the market89.
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CHAPTER 5
ANALYTICAL METHOD DEVELOPMENT
5.1     MATERIALS
Materials                      Suppliers
Irinotecan hydrochloride trihydrate Zydus Research Centre
Acetonitrile Merck specialities pvt ltd, Mumbai
Acetone Merck specialities pvt ltd, Mumbai
Table 5.1   List of materials
5.2 CALIBRATION CURVE OF IRINOTECAN IN ACETONITRILE
A stock solution of Irinotecan in ACN was prepared by dissolving 5 mg of
the drug in 50 ml of ACN. A serial dilution of stock solution was done to prepare
various strength of IRN solution and the absorbance was measured using UV Visible
spectrophotometer (UV-1700, Pharmaspec, Shimadzu, Japan) at wavelength of 256
nm. A calibration plot of absorbance vs. concentration was plotted.
5.3 CALIBRATION CURVE OF IRINOTECAN IN PHOSPHATE
BUFFER SALINE (PBS pH 7.4)
A stock solution of Irinotecan in PBS was prepared by dissolving 5 mg of
the drug in 50 ml of PBS. A serial dilution of stock solution was done to prepare
various strength of IRN solution and the absorbance was measured using UV Visible
spectrophotometer (UV-1700, Pharmaspec, Shimadzu, Japan) at wavelength of 256
nm. A calibration plot of absorbance vs. concentration was plotted.
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5.4       RESULTS AND DISCUSSION
The calibration curve of irinotecan hydrochloride trihydrate was carried out
in acetonitrile and phosphate buffer saline.
5.4.1  Calibration curve of IRN in ACN
Concentration MeanAbsorbance
0 0
10 0.708
20 1.455
30 2.105
40 2.731
50 3.221
Table 5.2:  data of calibration curve of IRN in acetonitrile at 256 nm
y= 10x-10   R2 = 1
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Figure 5.1: calibration curve of IRN in acetonitrile at 256 nm
The ?max in acetonitrile was 256 nm and the Beer- Lambert law was
followed in the range 0.5 to 2.5 mcg/ml concentration.
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5.4.2  Calibration curve of IRN in Phosphate buffer saline pH 7.4
    Concentration       Mean
Absorbance
0 0
5 0.558
10 0.866
15 1.308
20 1.726
25 2.232
Table 5.3 data of calibration curve of IRN in phosphate buffer pH 7.4 at 256 nm
Figure 5.2-calibration curve of IRN in phosphate buffer pH 7.4 at 256 nm
The ?max in phosphate buffer saline pH 7.4 was at 256 nm and the Beer-
Lambert law was followed in the range 0.5 to 2.5 mcg/ml concentration. Moreover
we observed regression coeffecient value of 0.990.
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5.5 POWDER X-RAY DIFFRACTION
Irinotecan hydrochloride was characterized by its powder X-ray diffraction
pattern,comprising 2? angle values of about 7.60; 8.30; 9.55; 11.00; and 12.40. The
Relative Intensity (%) of the mentioned characteristics reflection peaks of Form b at
the 2? angle values are reported in table.
Angle 2? Relative intensity %
7.60 47.9
8.30 33.4
9.55 36.9
11.00 97.3
12.40 88.1
Table 5.4 X-Ray diffraction pattern
Polymorphism' is the property of some molecules to adopt more than one
crystalline  form  in  the  solid  state.  A  single  molecule  can  give  rise  to  a  variety  of
solids having distinct physical properties that can be measured in a laboratory like its
thermal behavior, e.g. melting point and differential scanning calorimetry ("DSC")
thermogram, dissolution rate, flowability, X-ray diffraction pattern, infrared absorption
spectrum and NMR spectrum. The differences in the physical properties of polymorphs
result from the orientation and intermolecular interactions of adjacent molecules in the
bulk solid. Accordingly, polymorphs are distinct solids sharing the same molecular
formula which can yet have distinct advantageous and/or disadvantageous physical
properties compared to other forms in the polymorph family.
One property of a pharmaceutical compound that can vary depending upon
its polymorphic form is its rate of dissolution in aqueous solvent. The rate of
dissolution can have therapeutic consequences since it can affect the rate that an
orally administered pharmaceutical is delivered to the bloodstream of a patient.
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CHAPTER 6
FORMULATION DESIGN OF IRINOTECAN
HYDROCHLORIDE TRIHYDRATE NANOPARTICLES
6.1 LIST OF EQUIPMENT
Equipments Manufacturers
Micropipettes (tripett) 10?l ,1000?l, 100?l Ependorff ,Germany
Sonicator PRAMA Ultrasonic cleanser, Mumbai
U. V. Spectrophotometer Shimadzu UV-1601, Japan
Zeta sizer Malvern (Amili Ltd.), United Kingdom
Electronic Balance Mettler Toledo (Ag135), United states
Mettler Toledo electronic balance
(For weight less than 100mg)
Mettler Toledo (Ag135), United states
Centrifuge REMI Equipment, Delhi
Hot air oven Scientific equipment, India
Digital weighing balance Mettler Toledo, United States
Magnetic stirrer Tarsons spinot digital, Germany
6.2        MATERIALS
Materials Suppliers
Irinotecan hydrochloride trihydrate Zydus Research Centre, Ahemdabad
Poly(dl-lactide-co-glycolide)(50:50) Durect corporation, Birmingham
division, Pelham
Acetonitrile Merck specialities pvt ltd, Mumbai
Acetone Merck specialities pvt ltd, Mumbai
Poloxomer 188 Sigma chemical co., St Louis,USA
Poly vinyl alcohol Sigma chemical co., St Louis,USA
Sodium sulphate Canton laboratories pvt, ltd, Baroda,India
Sodium chloride Canton laboratories pvt, ltd, Baroda,India
Table 5.1 : list of materials
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6.3 FORMULATION OF IRN NANOPARTICLES
6.3.1  Nanoparticle preparation
a) Nanoparticles were prepared by using solvent evaporation method.
Polymer and drug was firstly dissolved in organic phase.
b) Then a weighed quantity of surfactant was dissolved in aqueous phase.
c) Then the organic phase was added to aqueous phase in a dropwise
manner.
d) The suspension was kept on mechanical stirring until the complete
evaporation of solvent.
e) The residual quantity of solvent was removed by rotatory vacuum
evaporator for 1 hour.
f) Then this dispersion was passed through the Sephadex G-25 column
(size exclusion chromatography) for the separation of free drug and
entrapped drug89.
Preparation of organic phase:  The  required  amount  of  the  organic  solvent  was
measured and was taken in a 10 ml beaker. Then drug and polymer was separately
weighed and was dissolved in organic phase.
Preparation of aqueous phase: the required amount of selected surfactant was
dissolved in water.
Serparation through Sephadex G-25 column: The  sephadex  G-  25  column  was
used to separate free drug and entrapped drug. This separation follows size exclusion
chromatography. In this separation an aliquot of nanoparticulate dispersion is passed
through the sephadex G-25 column. Firstly the free drug i.e. drug soluble in aqueous
phase is separated as a transparent solution through the column. Then the
nanoparticulate  suspension  comes  out  of  the  column  as  a  bluish  white  suspension
which is collected separately. The reason for this is that the internal pores of the
sephadex G-25 column will adjust the the paticles in size range of 10 – 500nm.
Hence the nanoparticles will be entrapped in the pores of column while the bigger
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particle size free drug will flow out through the at first succeeded by nanoparticles
which can be collected and further characterization can be performed.
Dissolve IRN and PLGA in organic phase (ACN/acetone)
Add it drop wise to aqueous surfactant (poloxomer 188/ PVA) solution
under continuous stirring
Continue stirring for complete solvent evaporation
IRN NP dispersion was passed through rotatory evaporator for 1 hour
Drug solution was passed through a Sephadex G-25 column
for removal of untrapped drug
Figure  6.1  Process Flow chart
6.3.2 Formulation optimization
The  aim  of  this  work  is  to  optimize  and  characterize  the  formulation
prepared by solvent evaporation method for the preparation of nanoparticles in order
to identify formulation and process parameters.
6.3.2.1 Process parameters
6.3.2.1.1 Selection of speed of the magnetic stirrer
a) The speed of magnetic stirrer at which nanoparticles are prepared
affects the particle size and percent drug entrapment due to different
evaporation rate.
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b) Different batches were prepared at various stirring speed of 400, 600
and  800  rpm  and  its  effect  on  the  nanoparticles  preparation  was
studied.
c) The particle size, PDI and percent drug entrapment were evaluated.
6.3.2.1.2 Effect of rate of addition of organic phase to aqueous phase:
a. The rate of addition of the organic phase to the aqueous phase
governs the formation of nanoparticles.
b. The speed at which the solvent is added will demonstrate its effect on
the formulation3.
c. For this purpose the rate of addition of solvent containing drug and
polymer to aqueous surfactant solution was kept at 0.25ml/min,
0.5ml/min and 1ml/min.
d. The effect of solvent addition rate on the particle size, PDI and
percent drug entrapment was evaluated.
6.3.2.2 Formulation parameters
6.3.2.2.1 Solvent selection (organic phase)
a. The  selection  of  organic  solvent  for  preparation  of  nanoparticles  by
solvent evaporation method is very essential.
b. So before formulation of nanoparticles one must have to select the
proper solvent in which the drug is maximum soluble in the range
which is essential in the nanoparticle drug delivery system3.
c. Acetonitrile and acetone are the most common of the solvents
reported for preparation of nanoparticles.
d. Both  the  solvents  were  used  initially  at  ratio  of  1:2  ratio  of
nanoparticulate system in aqueous phase keeping other parameters
constant.
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e. The  effect  of  these  solvents  on  particle  size,  PDI  and  percent  drug
entrapment was evaluated.
f. The IRN is insoluble in acetone, so it was dissolved in aqueous phase
and the nanoparticles were fabricated in ACN.
6.3.2.2.2 Surfactant Selection
a. Surfactant is a substance that reduces surface tension between the two
phases. Surfactant also aid in improving drug stability.
b. For formulating nanoparticle drug delivery system the stability of the
drug in different surfactants is an essential step.
c. So before formulation of nanoparticles one must have to select the
proper surfactant, which is essential in the nanoparticle drug delivery
system4.
d. In order to optimize the concentration of aqueous surfactant solution
in IRN NP, the nanoparticles were prepared by using PVA and
poloxomer188  concentrations  of  1%  to  2  %  each  and  other
parameters  were  kept  constant  and  their  effect  on  particle  size,  PDI
and percent drug entrapment was evaluated.
6.3.2.2.3 Effect of drug to polymer ratio on formulation
a) Drug  to  polymer  ratio  also  plays  a  vital  role  in  optimization  of  a
formulation.
b) The IRN NP with the different ratios of drug/PLGA i.e., 1:5, 1:10 and
1:20, were prepared keeping other parameters constant.
c) The amount of drug was kept constant while amount of polymer was
varied.  The  particle  size,  PDI  and  percent  drug  entrapment  were
evaluated.
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6.3.2.2.4 Effect of aqueous to organic phase ratio on formulation:
a) The aqueous to organic phase ratio in the nanoparticle formation was
also optimized, varying the amount of organic phase in three
different formulation batches and keeping the amount of aqueous
phase constant.
b) Here PLGA and drug were weighed and both drug and polymer were
dissolved in the 10ml (1:1), 5ml (1:2), 3.33 (1:3), 2.5ml (1:4)
acetonitrile for 4 different batches respectively.
c) The particle size, PDI and percent drug entrapment were evaluated.
6.3.2.2.5 Effect of poloxomer188 concentration on formulation:
a) The presence of surfactant molecules stabilizes the emulsion
nanodroplets and prevents them from coalescing with each other3.
b) In order to optimize the concentration of aqueous surfactant solution,
the IRN NP were prepared by using poloxomer-188 at various
concentrations of 1%, 2%, 3% and 4% each and other parameters
were kept constant.
c) The  effect  of  poloxomer188  on  particle  size,  PDI  and  percent  drug
entrapment was studied.
6.3.2.2.6 Effect of salt addition on formulation:
a) Two salts i.e. sodium sulphate and sodium chloride were used in
various concentrations i.e. 2%, 1%, 0.5% and 0.1%.
b) These salts were added in the aqueous phase along with the
surfactant. The effect of salt addition of IRN NP on the particle size,
PDI  and percent drug entrapment was evaluated.
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6.3.3  Characterization of IRN nanoparticles
6.3.3.1  Percent drug entrapment
a) An aliquot  of  IRN NP dispersion  was  added  to  CAN and sonicated
well to dissolve nanoparticles completely.
b) The absorbance of the solution was measured at ?max of 256nm
using U.V. visible spectrophotometer (UV-1700, Pharmaspec,
Shimadzu, Japan).
c) The percent drug entrapment was calculated using following formula.
                                                    Amount of drug in nanoparticles
Drug entrapment (%, w/w) =                                                                 ×  100
       Total amount of the drug used
6.3.3.1 Measurement of particle size and zeta potential:
a) The mean particle size, polydispersity index and zeta potential of
prepared IRN NP was measured using dynamic light scattering
method.
b) Briefly the IRN NP dispersion was filled in the cuvette and placed in
the zeta sizer ( Nano 25, Malvern, UK ).
c) Analysis was performed at 25 °C with an angle of detection of 90°.
d) Each reported value is the average of three measurements.
e) Each measurement was performed in triplicate and particle size, PDI
and zeta potential was measured.
6.3.3.4 Lyophilization of the IRN NP:
a) Here two cryoprotectants i.e. Sucrose and Trehalose were used at
different ratio of solid content to cryoprotectant.
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b) The ratio (w/w) of total solid content to cryoprtectant was selected
from 1:3, 1:5 and 1:7.
c) The cryoprotectants were dissolved in the IRN NP dispersion as per
different ratio and the vials were lyophilized using lyophilizer Vertis
Advantage, USA.
d) The total time for lyofilization was kept 36hrs.
e) After lyophilization, vials were removed and sealed immediately.
f) The lyophilized vials were reconstituted with 3ml of d.m. water
followed by 2 min bath sonication and particle size and PDI was
measured using zeta sizer (Nano ZS, UK).
6.3.3.5 Description of in vitro release process for IRN NP:
a. The in vitro drug release study for IRN NP was carried out using
dialysis method. Briefly the IRN NP dispersion equivalent to 1.5mg
of IRN was placed in dialysis tube of mol. wt 12,000 (Sigma Aldrich,
Mumbai).
b. The tube was sealed and dipped in a beaker 500ml of phosphate
buffer saline pH 7.4.
c. The buffer medium was stirred at speed of 100 rpm and the
temperature of medium was kept 37?20 C.
d. After certain time intervals, 3ml samples were withdrawn and the
media was replenished with same volume of fresh buffer using UV
visible spectrophotomer (UV-1700, Pharmaspec, Shimadzu, Japan)
and the percent cumulative drug release was calculated based on
calibration curve of IRN in PBS pH 7.4 (chapter3 section 3.3)
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CHAPTER 7
RESULT AND DISCUSSION
7.1 SELECTION OF SPEED OF THE MAGNETIC STIRRER:
The stirring speed of the mechanical stirrer for preparation of IRN NP was
kept at various rpm i.e. 400, 600, 800.  The effect of stirring speed on the particle
size, PDI and percent drug entrapment was evaluated and are shown in table 4.1.
Batch
code
Rotation per
minute
Particle
size (nm)
Poly
dispersivity
index
Percent drug
entrapment
IRNF024 800 211.6?10.4 0.154?0.020 30
IRNF025 600 218.3?12.5 0.116?0.023 33.82
IRNF026 400 336.5?14.7 0.302?0.019 26.082
Table 7.1   Effect of rotation speed
a) The water miscibility of the solvent is determining factor for
nanosuspension preparation.
b) At 600 rpm, high solubility of acetonitrile in water enables their fast
diffusion from dispersed droplets into aqueous phase.
c) Thus, as soon as the dispersed phase comes in contact with a large
amount of aqueous phase during the emulsion dilution, fast diffusion
of organic solvent occurs, leading to fast drug precipitation and
particle formation.
d) The finding obtained confirms that at higher speed (i.e 800 rpm) less
particle aggregation occurs but the PDI observed was very high
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compared to batch prepared at 600 rpm, which having similar particle
size with lower PDI.
e) Furthur at speed of 400rpm a aggregation was observed and resulted
into higher particle size3.
Hence the stirring speed was optimized to 600 rpm.
7.2  EFFECT OF RATE OF ADDITION OF ORGANIC PHASE TO
AQUEOUS PHASE
a) The rate of addition of solvent containing drug and polymer to
aqueous surfactant solution was varied to 0.25ml/min, 0.5ml/min and
1ml/min.
b) The effect of solvent addition speed on the nanoparticles preparation
was studied and following results were obtained.
Batch
code
Rate of
addition
Particle
size (nm)
Poly
dispersivity
index
Percent
drug
entrapment
IRNF027 0.25 ml/min 309.6?10.8 0.272?0.020 26
IRNF028 0.50ml/min 213.0?9.6 0.113?0.023 35.3
IRNF029 1 ml/min 245.6?12.1 0.192?0.024 21.3
Table 7.2 effect of rate of addition
c) The rate of addition of the organic phase to the aqueous phase
governs the formation of nanoparticles.
d) The speed at which the solvent is added will demonstrate its effect on
the formulation.
e) As shown in table 4.2, the rate of addition of organic phase at rate of
0.5 ml/min resulted into optimum particle size with lower PDI.
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f) In addition, the percent drug entrapment was higher compared to
other batches.
Hence from the above results it was clear that rate 0.5ml/min was the
optimum speed for the addition of the organic phase to aqueous phase.
7.3 SOLVENT SELECTION
a) For formulating nanoparticle drug delivery system the solubility of
the drug in different solvents is an essential step.
b) So before formulation of nanoparticles one must have to select the
proper solvent in which the drug is maximum soluble in the range
which is essential in the nanoparticle drug delivery system3.
c) In literature, various solvent lire CAN, DMSO, DMF, ethyl acetate
were used for preparation of PLGA NP’s.
d) Out of these two solvents are acetone and acetonitrile, which are
commonly reported in the literature for formation of PLGA NP’s.
Batch code
Solvent
Particle size
(nm)
Poly
dispersivity
index
Percent drug
entrapment
IRN F002 Acetone 336.1?12.3 0217?0.010 11.4
IRN F003 Actonitrile 223.2?10.3 0.113?0.014 34.2
Table 7.3 Effect of solvent
e) As shown in table 4.3 it was observed that IRN nanoparticles
prepared  using  acetonitrile  showed  lower  particle  size  and  PDI  and
had comparatively higher percent drug entrapment than acetone.
f) In acetone lower drug entrapment was observed because drug was
dissolved in aqueous phase for the preparation of IRN NP.
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Hence acetonitrile was selected was a solvent of choice for nanoparticle
preparation.
7.4 SURFACTANT SELECTION
a) In order to optimize the concentration of aqueous surfactant solution,
the nanoparticles were prepared by using PVA and Poloxomer188
concentrations  of  1%  to  2  %  each  and  other  parameters  were  kept
constant and results obtained are shown in table 4.4
b) Surfactant is a substance, which reduces surface tension between the
two phases. Surfactant also aid in improving drug stability.
c) For formulating nanoparticle drug delivery system the stability of the
drug in different surfactants is an essential step.
d) So before formulation of nanoparticles one must have to select the
proper surfactant, which is essential in the nanoparticle drug delivery
system.
e) The presence of surfactant molecules stabilizes the emulsion
nanodroplets and prevents them from coalescing with each other.
Batch
code Surfactant
Particle
size (nm)
Poly
dispersivity
index
Percent
drug
entrapment Remarks
IRNF004 1% PVA - - - Aggregationobserved
IRNF005 2%PVA - - - Aggregationobserved
IRNF006 1%Poloxomer188 445.3?11.4 0.342?0.010 25.3 Passed
IRNF007 1%Poloxomer188 218?10.2 0.108?0.013 33.82 Passed
Table 7.4 Surfactant selections
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f) For effective stabilization, the surfactant molecules must cover the
organic/aqueous interfacial area of all the droplets3.
g)  Hence a minimum number of surfactant molecules are required to
achieve small particle size and narrow size distribution.
h)  As shown in table 4.4, the batches prepared using  PVA showed
aggregation upon solvent evaporation.
Hence 2% of poloxomer-188 was selected as the surfactant of choice for
nanoparticle preparation.
7.5 DRUG: POLYMER (D: P) RATIO
a) Drug  to  polymer  ratio  also  plays  a  vital  role  in  optimization  of  a
formulation4.
b) The nanoparticles of IRN with the different ratios of drug: PLGA i.e.,
1:5, 1:10 and 1:20, were prepared using solvent evaporation method.
c) The amount of drug was kept constant while amount of polymer was
varied and results obtained are shown in table 4.5.
Batch
code
D:P
Ratio
Particle
size (nm)
Poly
dispersivity
index
Percent
drug
entrapment
Remarks
IRNF008 1:5 190.3?8.3 0.271?0.013 8.476 Failed
IRNF009 1:10 223.1?8.2 0.079?0.018 37.2 Passed
IRNF010 1:20 323.2?12.6 0111?0.010 6.32 Failed
Table 7.5 Effect of drug to polymer ratio
d) From the above observations, it observed that on decreasing the drug
to polymer ratio the particle size increased with decrease in the
percent drug entrapment.
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e) At 1:10 ratio of polymer an optimum particle size and percent drug
entrapment was observed.
Hence as a result the drug to polymer ratio was selected as 1:10.
7.6  AQUEOUS: ORGANIC PHASE RATIO
a) The aqueous to organic phase ratio was varied to note its effect on the
particle size and percent drug entrapment  Results obtained are
shown in table 4.6.
Batch
code
Aq:Or
Ratio
Particle
size (nm)
Poly
dispersivity
index
Percent
drug
entrapment
Remarks
IRNF011 1:1 - - - Aggregationwas observed
IRNF012 1:2 232.1?4.2 0.111?0.030 32.4 Passed
IRNF013 1:3 268.7?10.2 0.116?0.025 31.7 Passed
IRNF014 1:4 281.8?11.7 0.173?0.021 30.7 Passed
Table 7.6    Effect of aqueous to organic phase ratio
b) From  the  above  results  obtained,  it  was  noted  that  with  decrease  in
the volume of organic phase, resulted in the increase in particle size
and PDI of IRN NP.
c) A decrease in the percent drug entrapment was also noted.
d) However, we observed no difference in percent drug entrapment
upon changing ratio of aqueous to organic phase.
e) At 1:2 ratio we observed less particle size with low PDI.
Hence the aqueous to organic phase ratio was selected as 1:2.
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7.7       POLOXOMER188 CONCENTRATION
a) In order to optimize the concentration of aqueous surfactant solution,
the nanoparticles were prepared by using poloxomer-188 at
concentrations  of  1%,  2%,  3%  and  4%   and  other  parameters  were
kept constant. Results were obtained is summarized in the table 4.7.
Batch
code
Poloxomer188
concentration
Particle
size (nm)
Poly
dispersivity
index
Percent
drug
entrapment
IRNF015 1% 292.4?9.2 0.372?0.014 16.62
IRNF016 2% 221.3?10.6 0.172?0.010 35.64
IRNF017 3% 239.4?13.7 0.297?0.016 27.56
IRNF018 4% 243.6?10.3 0.201?0.013 25.23
Table 7.7     Effect of poloxomer 188 concentration
b) As the Poloxomer188 concentration is increased, the mean diameter
of nanoparticles increased.
c) As shown in table 4.7, it was observed that there was no any major
change in the particle size, but the PDI and percent drug entrapment
was altered.
d) The use of poloxomer188 at 3% & 4% concentration showed no
benefit compared to 2% poloxomer 1883.
Hence the poloxomer 188 concentration was selected as 2%.
7.8       SALT ADDITION
a) In order to increase percent drug entrapment two salts were used i.e.
sodium sulphate and sodium chloride in varying concentrations i.e.
2%, 1%, 0.5% and 0.1%. Results obtained are shown in table 4.8.
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Batch code Salt
concentration
Particle size
(nm)
Poly
dispersivity
index
Percent drug
entrapment
Remarks
IRNF018 Sodium sulphate
2%
- - - No formation of
nanoparticles
took place
IRNF019 Sodium sulphate
1%
- - - No formation of
nanoparticles
took place
IRNF020 Sodium sulphate
0.1%
247.9?20.3 0.397?0.012 23.87 Passed
IRNF021 Sodium chloride
1%
- - - No formation of
nanoparticles
took place
IRNF022 Sodium chloride
2%
- - - No formation of
nanoparticles
took place
IRNF023 Sodium chloride
0.1%
232.5?17.8 0.301?0.013 14.47 Passed
Table 7.8  Effect of salt addition
b) The  use  of  both  the  salt  resulted  into  increase  in  particle  size  with
decrease in drug entrapment at 0.1% concentration, while the 1% and
2% concentration of these salts did not induced nanoprecipitation and
IRN NP was notb formed.
c) Hence the use of salt  i.e.  NaCl and sodium sulphate showed no any
role increase in drug entrapment with maintenance of particle size
near to 200nm3.
            So no salts were added to the formulation.
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7.9        IN VITRO RELEASE PROFILE OF IRN NP
The in vitro release pattern of IRN NP is represented in table 4.9 and figure 4.1
Time Cumulative Percentdrug  release
  15 min           0
  30 min           0.4
  1 hours          1.3
  2 hours          4.75
  4 hours         20.59
  6 hours         31.85
  8 hours         48.32
 24 hours       87.3
Table 7.9 In vitro profile of IRN NP
                   Figure 7.1  a plot showing in vitro release pattern of IRN NP
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a) The drug release profile of IRN NP showed sustained release of drug
over 24 hours.
b) A initial burst release of 20.59 was observed at 4hour followed by
sustained release.
c) The results obtained are in similar fashion of other water-soluble drug
entrapped in PLGA NP’s3.
7.10      LYOFILIZATION OF IRN NP
a) Lyophilized  IRN  NP  with  different  cryoprotectant  at  various  ratios
were reconstituted with d.m. water and following data were obtained.
Batch code  Cryoprotectants  Particle size       PDI
IRNF030 Sucrose 1:3   367.1? 20.1  0.203?0.023
IRNF031 Sucrose 1:5   277.2? 10.2  0.227?0.025
IRNF032 Sucrose 1:7   284.2? 13.3  0.256?0.015
IRNF033 Trehalose1:3   215.5? 11.4  0.112?0.010
IRNF034 Trehalose1:5   186.1? 16.4  0.094?0.013
IRNF035 Trehalose1:7   198.1? 12.8  0.101?0.006
Table 7.10: Lyofilization of IRN NP
b) Trehalose as a cryoprotectant at ratio of 1:3 showed particle size after
reconstitution near to the initial particle size.
c) The trehalose at higher ratio (1:5 and 1:7) showed minor change in
particle size and PDI.
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d) It was found that trehalose at 1:3 ratio showed comparatively better
cryoprotective behavior to other ratio of trehalose and sucrose.
e) Trehalose seems to be a preferable cryoprotectant for biomolecules.
f) It has many advantages in comparison with the other sugars as: less
hygroscopicity, an absence of internal hydrogen bounds which allows
more flexible formation of hydrogen bonds with nanoparticles during
freeze-drying, very low chemical reactivity and finally, higher glass
transition temperature Tg?52.
7.11     PARTICLE SIZE AND ZETA POTENTIAL MEASUREMENT:
a) The particle size and zeta potential was measured using zeta sizer
(Nano ZS, Malvern, UK).
b) Zeta  potential  is  the  overall  charge  acquired  by  particles  in  a
particular medium and its value gives the indication of potential
physical stability of nanoparticles dispersion.
c) If all the particles have large positive or negative of zeta potential
they will repel each other and system is considered to be stable.
d) Higher the value, more stable the system.
e) The zeta potential obtained was –13.3 mV. The particle size and zeta
potential are shown in figure 4.2 and 4.3 respectively.
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Figure 7.2   Particle size of IRN NP
Figure 7.3  Zeta potential of IRN NP
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CHAPTER 8
SUMMARY AND CONCLUSION
Summary
As the field of targeted drug delivery continues to move forward, it will be
increasingly important to design nanoscale systems with tailorable properties for
efficient delivery and improved therapeutic efficacy. Important design
considerations will include the physicochemical properties that govern targeting,
biodistribution, and clearance as well as the system’s effectiveness in carrying,
protecting, and even releasing active therapeutic and diagnostic agents. The
formulation, optimization and characterization of  irinotecan hydrochloride
trihydrate nanoparticles was successfully carried out.
Conclusion
1. The analytical method developed for IRN in ACN and PBS pH 7.4
showed regression coeffecient near to 1 and followed Beer Lambert’s
law.
2. Irinotecan PLGA nanoparticles were prepared using solvent
evaporation method.
3. Formulation and optimization of  IRN  NP  was  carried  out  using
various formulation and process parameters.
4. Solvent selection: Acetonitrile was selected as the solvent of choice
5. Surfactant selection: Poloxomer 188 was selected as surfactant.
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6. Drug to polymer ratio: The drug to polymer ratio was optimized to
be 1:10
7. Organic phase to aqueous phase ratio: The organic phase to
aqueous phase ratio was optimized as 1:2.
8. Poloxomer 188 concentration: The poloxomer188 concentration
was selected as 2%.
9. RPM of the magnetic stirrer: The speed of rotation of the magnetic
stirrer was kept 600 rpm
10. Rate of addition of organic phase to aqueous phase:  The  rate  of
addition of organic solvent to the aqueous solvent was 0.5 ml/min.
11. Zeta potential: Zeta potential is the overall charge acquired by
particles in a particular medium and its value gives the indication of
potential physical stability of nanoparticles dispersion. The zeta
potential obtained was –13.3 mV.
12. Percent drug entrapment: The maximum percent drug entrapment
was found out to be 37.2% of the batch IRN F009.
13. In vitro drug release: The in vitro drug release of IRN NP was also
found out using dialysis method in phosphate buffer saline pH 7.4.
The in vitro drug release showed sustained release of drug over 24
hours.
14. Lyofilization: Lyophilized IRN NP with different cryoprotectant at
Svarious ratios of solid drug to cryoprotectants was used. Compared
to sucrose, trehalose served as better cryoprotectant and maintained
the original particle size.
Hence the IRN loaded PLGA nanoparticles have potential as a drug
delivery system. Furthermore, they may have utility for site-specific drug delivery
since the small size of the particles may allow their delivery to extra vascular target
sites through the leaky endothelia of inflamed and cancerous areas.
Department of Pharmaceutics                               Bibliography
Annai Veilankannis Pharmacy College, Chennai
67
CHAPTER 9
BIBLIOGRAPHY
1) Surendiran, S. Sandhiya, S.C. Pradhan & C. Adithan, Novel applications of
nanotechnology in medicine, Indian J Med Res 130, December 2009, pp
689-701.
2) Hatefi, B. Amsden, Biodegradable injectable in situ forming drug delivery
systems, Journal of Controlled Release 80 (2002) 9–28.
3) Avinash Budhian , Steven J. Siegel , Karen I Winey, Haloperidol-loaded
PLGA nanoparticles: Systematic study of particle size and drug content,
Pharmaceutical Nanotechnology, International Journal of Pharmaceutics 336
(2007) 367–375.
4) Alaa Eldeen B. Yassin, Md. Khalid Anwer, Hammam A. Mowafy, Ibrahim
M. El-Bagory, Mohsen A. Bayomi1, and Ibrahim A. Alsarra, Optimization
of 5-fluorouracil solid-lipid nanoparticles: a preliminary study to treat colon
cancer, International Journal of Medical Sciences 2010; 7(6): 398-408.
5) Akansha Tripathi, Ranjana Gupta, Shubhini A. Saraf, PLGA nanoparticles
for antitubercular drug: Drug Loading and Release Studies of a Water In-
Soluble Drug, International Journal of PharmTech Research, July-Sept 2010,
Vol.2, No.3, pp 2116-2123.
6) Anderson J.M. and Shive M.S., Biodegradation and biocompatibility of PLA
and PLGA microspheres, Adv. Drug. Delivery Rev., 1997, 28, 5–24.
7) Astete, C. E. and Sabliov, C. M. (2006). "Synthesis and characterization of
PLGA nanoparticles." Journal of Biomaterials Science-Polymer Edition
17(3): 247-289.
Department of Pharmaceutics                               Bibliography
Annai Veilankannis Pharmacy College, Chennai
68
8) Ali Mohammadi, Farnaz Esmaeili, Simultaneous Determination of Irinotecan
Hydrochloride and its Related Compounds by High Performance Liquid
Chromatography Using Ultraviolet Detection, Asian Journal of Chemistry,
Vol. 22, No. 5 (2010), 3966-3972.
9) Åsgeir Helland, Nanoparticles: A Closer Look at the Risks to Human Health
and the Environment: Perceptions and Precautionary Measures of Industry
and Regulatory Bodies in Europe, IIIEE, Lund University, ISSN 1650-1675.
10) Beeta Ehdaie, Application of Nanotechnology in Cancer Research: Review
of Progress in the National Cancer Institute’s Alliance for Nanotechnology,
International Journal of Biological Sciences, 108-110, 2007.
11) Basudev Sahana, Kousik Santra, Sumit Basu and Biswajit Mukherjee,
Development of biodegradable polymer based tamoxifen citrate loaded
nanoparticles and effect of some manufacturing process parameters on them:
a physicochemical and in-vitro evaluation, International Journal of
Nanomedicine 2010:5 621–630.
12) Bhupendra G. Prajapati, Nanoparticles As Platforms For Targeted Drug
Delivery System In Cancer Therapy, The Internet journal of nanotechnology,
Volume 3 Number 1, 2009.
13) Bexhill-on-Sea, What is Cancer? What Causes Cancer?,UK
MediLexicon International Ltd, 2004-2011.
14) Camile Baldin Woitiski , Francisco Veiga , António Ribeiro , Ronald
Neufeld, Design for optimization of nanoparticles integrating biomaterials
for orally dosed insulin, European Journal of Pharmaceutics and
Biopharmaceutics 73 (2009) 25–33.
15) Cristina Fonsecaa, Se´rgio Simo˜esa,b , Roge´rio Gaspara, Paclitaxel-loaded
PLGA nanoparticles: preparation, physicochemical characterization and in
vitro anti-tumoral activity, , Journal of Controlled Release 83 (2002) 273–
286.
Department of Pharmaceutics                               Bibliography
Annai Veilankannis Pharmacy College, Chennai
69
16) Cell cycle control and cancer, Michelle D. Garrett, Current science, volume
81, no.5, 10 September 2001.
17) Chen Fang, Narayan Bhattarai, Conroy Sun, and Miqin Zhang*,
Functionalized Nanoparticles with Long-Term Stability in Biological
Media**, NIH Public Access, 2009 July; 5(14): 1637–1641.
18) Douglas Hanahan, The Hallmarks of Cancer, and Robert A.   Weinberg†,
Cell, Vol. 100, 57–70, January 7, 2000.
19) Donald E. Owens III, Nicholas A. Peppas Opsonization, biodistribution, and
pharmacokinetics of polymeric nanoparticles, International Journal of
Pharmaceutics 307 (2006) 93–102.
20) David Cameroon, Cancer, Life sciences at Whitehead Institute for
Biomedical Research, paradigm, spring 2009.
21) Derfus, A. M., Chan, W. C. W., and Bhatia, S. N., Intracellular delivery of
quantum dots for live cell labeling and organelle tracking, Advanced
Materials, 16, 961–966, 2004.
22) Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev
Cancer 2005; 5:161–171.
23) F. Franks, Freeze-drying of bioproducts: putting principles into practice, Eur.
J. Pharm. Biopharm. 45 (1998) 221–229.
24) F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. BerkV.P. Torchilin,
R.K. Jain, Vascular permeability in humantumour xenograft: molecular size
dependence and cut-offsize, Cancer Res. 55 (1995) 3752–3756.
25) Poovi, U.M. Dhanalakshmi, N. Narayanan, Preparation and characterization
of Repaglinide loaded chitosan polymeric nanoparticles, research journal of
Nanoscience and Nanotechnology, 1 (1), 12-24, 2011.
Department of Pharmaceutics                               Bibliography
Annai Veilankannis Pharmacy College, Chennai
70
26) Gert  Storm,  Sheila  0.  Belliot,  Toos  Daemenb,  Danilo  D.  Lasic,  Surface
modification of nanoparticles to oppose uptake by the mononuclear
phagocyte system, Advanced Drug Delivery Reviews 17 (1995) 31-48.
27) Gambhir SS. Molecular imaging of cancer with positron emission
tomography. Nat Rev Cancer 2002; 2:683–693.
28) Gref, R., Minamitake, Y., et al. (1994). "Biodegradable Long-Circulating
Polymeric Nanospheres." Science 263(5153): 1600-1603.
29) Gabor, F., Ertl, B., Wirth, M., Mallinger, R., 1999. Ketoprofen-poly (d,l-
lacticco glycolic acid) microspheres: influence of manufacturing parameters
and type of polymer on the release characteristics. J. Microencapsul. 16,1-12.
30) Galindo-Rodriguez, S., Allemann, E., Fessi, H., Doelker, E., 2004.
Physicochemical parameters associated with nanoparticle formation in the
salting-out, emulsification-diffusion and nanoprecipitation methods. Pharm.
Res. 21, 1428–1439.
31) Gorner, T., Gref, R., Michenot, D., Sommer, F., Tran, M.N., Dellacherie, E.,
1999. Lidocaine-loaded biodegradable nanospheres. I. Optimization of the
drug incorporation into the polymer matrix. J. Control. Release 57, 259–268.
32) Redhead, S.S. Davis, L. Illum, Drug delivery in poly (lactide-co-glycolide)
nanoparticles surface modified with poloxamer 407 and poloxamine 908: in
vitro characterisation and in vivo evaluation, Journal of Controlled Release
70 (2001) 353–363.
33) Parshad, K. Frydenvang, T. Liljefors, C. Cornett, and C. Larsen. Assessment
of drug salt release from solutions, suspensions and in situ suspensions using
a rotating dialysis cell. Eur. J. Pharm. Sci. 19:263Y272 (2003).
34) Hiroshi Maeda, Enhanced Permeability and Retention (EPR) in tumor
vasculature, Advanced Enzyme Regulation, Vol. 41, pp. 189–207, 2001.
Department of Pharmaceutics                               Bibliography
Annai Veilankannis Pharmacy College, Chennai
71
35) Ibrahim, N. K., Desai, N., et al. (2002). "Phase I and pharmacokinetic study
of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation
of paclitaxel." Clinical Cancer Research 8(5): 1038-1044.
36) Irinotecan Hydrochloride, The United States Pharmacopeial Convention,
Revision Bulletin, Official October 1, 2010.
37) Irinotecan Hydrochloride, Oncologic Drug Advisory Committee Brochure,
Supplement #9, March 16, 2000.
38) Irinotecan Hydrochloride, The United States Pharmacopeial Convention,
2009.
39) Irinotecan hydrochloride Trihydrayte, Drug Bank, June 13, 2005.
40) James M. Anderson*, Matthew S. Shive, Biodegradation and
biocompatibility of PLA and PLGA microspheres Advanced Drug Delivery
Reviews 28 (1997) 5–24.
41) Jiang, W. L., Gupta, R. K., et al. (2005). "Biodegradable poly(lactic-co-
glycolic acid) microparticles for injectable delivery of vaccine antigens."
Advanced Drug Delivery Reviews 57(3): 391-410.
42) J.H. Crowe, F.A. Hoekstra, L.M. Crowe, Anhydrobiosis, Annu. Rev.
Physiol. 54 (1992) 579–599.
43) Justin Blanchard and Alciades Velasquez, Nanoparticles and Nanospheres
for Controlled Drug Delivery Systems, Research Project, 2000.
44) Jianjun Chenga, Benjamin A. Teplya, , Ines Sherifia, , Josephine Sunga,
Gaurav Luthera, Frank X. Gua,b, Etgar Levy-Nissenbauma,b,c, Aleksandar F.
Radovic-Morenob,d, Robert Langera,b,d, Omid C. FarokhzadbFormulation
of functionalized, PLGA–PEG nanoparticles for in vivo targeted drug
delivery, Biomaterials 28 (2007) 869–876.
Department of Pharmaceutics                               Bibliography
Annai Veilankannis Pharmacy College, Chennai
72
45) Schultz, B. Mollgaard, S. Frokjaer, and C. Larsen. Rotating dialysis cell as in
vitro release method for oily parenteral depot solutions. Int. J. Pharm.
157:163Y169 (1997).
46) Sampath Kumar, Debjit Bhowmik, Chiranjib, Margret Chandira, Innovations
in Sustained Release Drug Delivery System and Its Market Opportunities,
Journal  of  Chemical  and  Pharmaceutical  Research,  J.  Chem.  Pharm.  Res.,
2010, 2(1): 349-360.
47) Karen I. Avinash Budhian, Steven J. Siegel, Winey Haloperidol-loaded
PLGA nanoparticles: Systematic study of particle size and drug content,
Pharmaceutical Nanotechnology, International Journal of Pharmaceutics 336
(2007) 367–375.
48) Khosro Adibkiaa, Yousef Javadzadeha,, Siavoush Dastmalchia,, Ghobad
Mohammadic, Fatemeh Kari Niri , Mahmood Alaei-Beiramia, Naproxen–
eudragit RS100 nanoparticles: Preparation and physicochemical
characterization, Colloids and Surfaces B: Biointerfaces 83 (2011) 155–159.
49) Kumaresh S. Soppimatha, Tejraj M. Aminabhavia , Anandrao R. Kulkarnia,
b Walter E. Rudzinski,Biodegradable polymeric nanoparticles as drug
delivery devices, Journal of Controlled Release 70 (2001) 1–20.
50) Kwangjae Cho, Xu Wang, Shuming Nie, et al., Therapeutic Nanoparticles
for Drug Delivery in Cancer, American Association of Cancer Research,
Clin Cancer Res 2008; 14:1310-1316. Published online March 3, 2008.
51) Loredana Serpe, Conventional Chemotherapeutic Drug Nanoparticles for
Cancer Treatment, Nanotechnologies for the Life Sciences Vol. 6, 2006 pg
no. 1-39.
52) Crowe, D.S. Reid, J.H. Crowe, Is trehalose special for preserving dry
materials? Biophys. J. 71 (1996) 2087–2093.
53) Matthias Rath, M.D., Cellular Health Series: Cancer, First Edition, February
2001, pg no 1-40.
Department of Pharmaceutics                               Bibliography
Annai Veilankannis Pharmacy College, Chennai
73
54) Mauro Ferrari, Cancer Nanotechnology: Opportunities and challenges,
Nature reviews, volume 5, March 2005, page no. 161-171.
55) Hans, A.M. Lowman*, Biodegradable nanoparticles for drug delivery and
targeting, Current Opinion in Solid State and Materials Science, 6 (2002)
319–327.
56) Muthu, Nanoparticles based on PLGA and its copolymers: An overview,
Asian journal of pharmaceutics, October- November 2009, p. 35-75.
57) Margaret A. Phillips a, Martin L. Granb, Nicholas A. Peppas, Targeted
nanodelivery of drugs and diagnostics, Nano Today (2010) 5, 143—159.
58) Montet  X,  Montet-Abou  K,  Reynolds  F,  et  al.  Nanoparticle  imaging  of
integrins on tumor cells. Neoplasia 2006; 8:214–222.
59) Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK.
Chitosan–sodium alginate nanoparticles as submicroscopic reservoirs for
ocular delivery: formulation, optimization and in vitro characterization. Eur.
J. Pharm. Biopharm. 2008; 68:513–525.
60) Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific
nanoparticles: theory to practice. Pharmacol Rev 2001; 53: 283–318.
61) N. A. Kshirsagar, Drug delivery system, Indian Journal of Pharmacology
2000; 32: S54-S61.
62) Omathanu Pillai and Ramesh Panchagnula, Polymers in drug delivery,
Current Opinion in Chemical Biology 2001, 5:447–451.
63) Park, J. W. Liposome-based drug delivery in breast cancer treatment. Breast
Cancer Res. 4, 95–99 (2002).
64) Panyam, J. and Labhasetwar, V. (2003). "Biodegradable nanoparticles for
drug and gene delivery to cells and tissue." Advanced Drug Delivery
Reviews 55(3): 329-347.
Department of Pharmaceutics                               Bibliography
Annai Veilankannis Pharmacy College, Chennai
74
65) Richard Clapp, D.Sc., Genevieve Howe, MPH, Molly Jacobs Lefevre, MPH,
Environmental and Occupational Causes of Cancer, A Review of Recent
Scientific Literature, September 2005, pg no. 1-50.
66) R. Gref”‘“, A. Dombb, P. Quelled’, T. Blunk’, R.H. Miillerd, J.M.
Verbavatz”, the controlled intravenous delivery of drugs using PEG-coated
sterically stabilized nanospheres, Advanced Drug Delivery Reviews 16
(1995) 215-233.
67) Rubiana M. Mainardes, Raul C. Evangelista, PLGA nanoparticles containing
praziquantel: effect of formulation variables on size distribution International
Journal of Pharmaceutics 290 (2005) 137–144.
68) Richard Clapp, Genevieve Howe, Molly Jacobs Lefevre, Environmental and
Occupational Causes of Cancer, A Review of Recent Scientific Literature,
Cancer Working Group of the Collaborative on Health and the Environment,
September 2005, 1-1340.
69) Ruoslahti, E., Antiangiogenics meet nanotechnology, Cancer Cell, 2, 97–98,
and 2002.
70) Salvatore A. Velardi, Antonello A. Barresi, Development of simplified
models for the freeze-dryin process and investigation of the optimal operating
conditions, chemical engineering research and design 86 (2008) 9- 22.
71) Susan S. D’Souza and Patrick P. DeLuca Methods to Assess in Vitro Drug
Release from Injectable Polymeric Particulate Systems, Pharmaceutical
Research, Vol. 23, No. 3, March 2006, 7-35.
72) Sunny Y. Auyang, Cancer causes and cancer research on many levels of
complexity, http://www.creatingtechnology.org/biomed/cancer.pdf.
73) Srinivas, P. R., Barker, P. & Srivastava, S. Nanotechnology in early
detection of cancer. Lab. Invest. 82, (2002), 657–662.
74) Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment.
Curr Drug Deliv 2005; 2:369–381.
Department of Pharmaceutics                               Bibliography
Annai Veilankannis Pharmacy College, Chennai
75
75) chellenberger EA, Bogdanov A Jr, Petrovsky A, et al. Optical imaging of
apoptosis  as  a  biomarker  of  tumor  response  to  chemotherapy.  Neoplasia
2003; 5:187–192.
76) Thirumala Govender, Snjezana Stolnik*, Martin C. Garnett, Lisbeth Illum,
Stanley S. Davis, PLGA nanoparticles prepared by nanoprecipitation: drug
loading and release studies of a water soluble drug, Journal of Controlled
Release 57 (1999) 171–185.
77) The United States Pharmacopeial Convention, Irinotecan Hydrochloride,
Revision Bulletin Official October 1, 2010
78)  U. S. P. 25. Rockville, MD, 2002, pp. 2011-2019.
79)  U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, Cancer
Nanotechnology, National Institutes of Health National Cancer Institute,
January 2004.
80)  U.S. National Institute of health, what is cancer? National Cancer Institute,
www. Cancer. Gov.
81)  Vandervoort J. and Ludwig A., Biocompatible stabilizers in the preparation
of PLGA nanoparticles: a factorial design study, Int. J. Pharm., 2002, 238,
79–92.
82)  Vladimir P. Torchilin, Drug targeting, Department of Pharmaceutical
Sciences, School of Pharmacy, Bouve College of Health Sciences,
Northeastern University, Boston, MA 02115, USA, November 2000.
83)  Vivek  Kumar  Gupta,  V.K.  Karar,  Optimization  of  process  variables  for  the
preparation of chitosan- alginate nanoparticles, International Journal of
Pharmacy and Pharmaceutical Sciences, Vol 3, Suppl 2, 2011, 78-80.
84)  Vikram  M.  Pandya*,  Jayvadan  K.  Patel  and  Dhaval  J.  Patel,  Formulation,
Optimization and characterization of Simvastatin Nanosuspension prepared
by nanoprecipitation technique, Scholar Research Library, Der Pharmacia
Lettre, 2011, 3(2): 129-140.
Department of Pharmaceutics                               Bibliography
Annai Veilankannis Pharmacy College, Chennai
76
85)  V. Labhasetwar, A.K. Dorle, Nanoparticles—a colloidal drug and dissolution
behaviours of microspheres prepared by three delivery system for
primaquine and metronidazole, J. Con- low molecular weight polyesters, J.
Microencapsul. 17 control. Release 12 (1990) 113–119. (2000) 577–586.
86)  V. Labhasetwar, C. Song, W. Humphrey, R. Shebuski, R.J.  J.L. Cleland,
O.L. Johnson, S. Putney, A.J.S. Jones, Recom-Levy, Arterial uptake of
biodegradable nanoparticles: effect binant human growth hormone
poly(lactic-co-glycolic acid) of surface modifications, J. Pharm. Sci. 87
(1998) 1229– microsphere formulation development, Adv. Drug Del. Rev.
1234. 28 (1997) 71–84.
87)  V. Labhasetwar, J. Bonadio, S.A. Goldstein, R.J. Levy, Gene [29] C.
Berkland, M. King, A. Cox, K. Kim, D.W. Pack, Precise transfection using
biodegradable nanospheres: results in control of PLG microsphere size
provides enhanced control tissue culture and a rat osteotomy model, Colloids
Surfaces of drug release rate, J. Control. Release 82 (2002) 137–147. B:
Biointerfaces 16 (1999) 281–290.
88)  William R. Sellers and David E. Fisher, Apoptosis and cancer drug targeting,
The  Journal  of  Clinical  Investigation,  Volume  104,  Number  12,  December
1999, p. 1-240.
89)  Wang Chungxia, Wheat germ agglutinin PLGA nanoparticles for enhanced
uptake, retention of paclitaxel by colon cancer cells, Department of
pharmacy, National institute of Singapore, 2009, p.1-135.
90)  Wassim Abdelwahed , Ghania Degobert , Serge Stainmesse , Hatem Fessi,
Freeze-drying of nanoparticles: Formulation, process and storage
considerations, Advanced Drug Delivery Reviews 58 (2006) 1688–1713.
91)  Xue Shen Wu and Nou Wang, J. Synthesis, characterization, biodegradation,
and drug delivery application of biodegradable lactic/ glycolic acid
polymers. Part II: Biodegradation, Biomater. Sci. Polymer Edn, Vol. 12, No.
1, pp. 21–34 (2001).
Department of Pharmaceutics                               Bibliography
Annai Veilankannis Pharmacy College, Chennai
77
92)  Yvette Meissner, Yann Pellequer, Alf Lamprecht, Nanoparticles in
inflammatory bowel disease: Particle targeting versus pH-sensitive delivery,
International Journal of Pharmaceutics 316 (2006) 138–143.
93)  Zweers, M.L.T., Grijpma, D.W., Engbers, G.H.M., Feijen, J., The
preparation of monodisperse biodegradable polyester nanoparticles with a
controlled size. J. Biomed. Mater. Res. Part B: Appl. Biomater. 66B, 2003,
559–566.
